var title_f29_31_30192="Adenomyosis 6a";
var content_f29_31_30192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53441&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    35-year-old woman with menorrhagia and dysmenorrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal fast spin-echo T2-weighted MR image obtained before embolization shows global uterine enlargement and diffuse adenomyosis. Junctional zone thickness (arrow) is 14 mm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30192=[""].join("\n");
var outline_f29_31_30192=null;
var title_f29_31_30193="Patient information: Chemical eye injury (The Basics)";
var content_f29_31_30193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17205\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29105\">",
"         Parts of the eye",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/9/43153\">",
"         Patient information: Corneal abrasion (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Chemical eye injury (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/chemical-eye-injury-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13207700\">",
"      <span class=\"h1\">",
"       What is a chemical eye injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A chemical eye injury is when a chemical gets into the eye and harms it. Different types of chemicals can cause a chemical eye injury. Examples include chemicals found in cleaning products, bleach, hair dyes, and lawn fertilizers.",
"     </p>",
"     <p>",
"      Some chemicals cause only mild or short-term symptoms. Other chemicals can cause severe damage, including scarring of the cornea (the clear tissue that covers the colored part of the eye) or vision loss (",
"      <a class=\"graphic graphic_figure graphicRef70420 \" href=\"UTD.htm?28/27/29105\">",
"       figure 1",
"      </a>",
"      ). How mild or serious an injury is depends on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The type of chemical",
"       </li>",
"       <li>",
"        How long the chemical is in the eye",
"       </li>",
"       <li>",
"        How far into the eye the chemical spreads",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207715\">",
"      <span class=\"h1\">",
"       What are the symptoms of a chemical eye injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble seeing",
"       </li>",
"       <li>",
"        Eye pain",
"       </li>",
"       <li>",
"        Being unable to open your eye",
"       </li>",
"       <li>",
"        Redness of the white part of your eye",
"       </li>",
"       <li>",
"        Bright light bothering your eye",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207730\">",
"      <span class=\"h1\">",
"       Is there anything I should do on my own to treat a chemical eye injury?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You should wash the chemical out of your eye right away with water. You can put your eye under a faucet or shower. Use cool water, and try to wash out your eye for 15 to 30 minutes. If you have contact lenses in, do not remove your lenses first. If the chemical got only in 1 eye, keep your other eye closed so the chemical doesn&rsquo;t flow into that eye. Do not rub or press on your eye.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207745\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. After you wash out your eye, see a doctor or nurse right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207760\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You will not need tests. But your doctor or nurse will ask about your symptoms and the chemical that got in your eye, and do an exam.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207775\">",
"      <span class=\"h1\">",
"       How is a chemical eye injury treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The doctor or nurse will continue to wash the chemical out of your eye. Depending on the chemical, this can last hours.",
"     </p>",
"     <p>",
"      Other treatment will likely include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain-relieving eye drops",
"       </li>",
"       <li>",
"        Eye drops or ointments to help prevent an infection",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on your injury, you might also need to see an eye specialist.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207790\">",
"      <span class=\"h1\">",
"       Can a chemical eye injury be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can help prevent a chemical eye injury by wearing safety glasses or goggles when you work with chemicals. To prevent a chemical eye injury in your child, keep cleaning supplies out of your child&rsquo;s reach.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13207805\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/9/43153?source=see_link\">",
"       Patient information: Corneal abrasion (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/31/30193?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17205 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-08BE826B45-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30193=[""].join("\n");
var outline_f29_31_30193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207700\">",
"      What is a chemical eye injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207715\">",
"      What are the symptoms of a chemical eye injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207730\">",
"      Is there anything I should do on my own to treat a chemical eye injury?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207745\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207760\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207775\">",
"      How is a chemical eye injury treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207790\">",
"      Can a chemical eye injury be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13207805\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17205\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29105\">",
"      Parts of the eye",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/9/43153?source=related_link\">",
"      Patient information: Corneal abrasion (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30194="T-shaped acetabular fracture";
var content_f29_31_30194=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F54187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F54187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Radiographic appearance of T-shaped acetabular fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 469px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The appearance on the anteroposterior pelvis radiograph may be distinguished from the transverse fracture by the presence of the fracture of the ischial ramus (white arrow). Displacement of the stem of the T may cause the ilioischial line to appear duplicated (black arrowheads). Likewise, the relationship between the ilioischial line, which remains with the posterior column, and the teardrop, which remains with the anterior column, may be disrupted (black arrow).",
"    <br/>",
"    (B) The obturator oblique shows the break in the iliopectineal line (black arrow). It also allows better visualization of the stem of the T (white arrow) as it enters the roof of the obturator foramen and is associated with the ischial ramus fracture (arrowhead).",
"    <br/>",
"    (C) The iliac oblique view demonstrates the disruption of the greater sciatic notch and subluxation of the femoral head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Originally published in: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults, 7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Reproduced with permission. Copyright &copy; Berton R. Moed, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30194=[""].join("\n");
var outline_f29_31_30194=null;
var title_f29_31_30195="Splinter hemorrages 1";
var content_f29_31_30195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Splinter hemorrages of the great toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 428px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Trauma-induced splinter hemorrages are typically located in the distal nail plate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30195=[""].join("\n");
var outline_f29_31_30195=null;
var title_f29_31_30196="Propylthiouracil: Patient drug information";
var content_f29_31_30196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Propylthiouracil: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=see_link\">",
"     see \"Propylthiouracil: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"     see \"Propylthiouracil: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F215073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Propyl-Thyracil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10168463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems in some patients. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat an overactive thyroid gland.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702814",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to propylthiouracil or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697732",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for 1 month after stopping this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698411",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your baby's thyroid checked if you are using this drug and breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695848",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug around-the-clock.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11006 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-B09A38F648-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30196=[""].join("\n");
var outline_f29_31_30196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215073\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10168463\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027983\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027982\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027987\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027988\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027990\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027985\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027986\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027991\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027992\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/9/5271?source=related_link\">",
"      Propylthiouracil: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=related_link\">",
"      Propylthiouracil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30197="Enalapril: Patient drug information";
var content_f29_31_30197=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Enalapril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     see \"Enalapril: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=see_link\">",
"     see \"Enalapril: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F164751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vasotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F164752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Enalapril&reg;;",
"     </li>",
"     <li>",
"      CO Enalapril;",
"     </li>",
"     <li>",
"      Mylan-Enalapril;",
"     </li>",
"     <li>",
"      Novo-Enalapril;",
"     </li>",
"     <li>",
"      PMS-Enalapril;",
"     </li>",
"     <li>",
"      PRO-Enalapril;",
"     </li>",
"     <li>",
"      RAN&trade;-Enalapril;",
"     </li>",
"     <li>",
"      ratio-Enalapril;",
"     </li>",
"     <li>",
"      Riva-Enalapril;",
"     </li>",
"     <li>",
"      Sandoz-Enalapril;",
"     </li>",
"     <li>",
"      Sig-Enalapril;",
"     </li>",
"     <li>",
"      Taro-Enalapril;",
"     </li>",
"     <li>",
"      Teva-Enalapril;",
"     </li>",
"     <li>",
"      Vasotec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10022892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect kidney function in diabetic patients who have protein loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022893\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to enalapril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries or hyperaldosteronism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022898\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022899\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022901\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022896\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022897\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12414 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30197=[""].join("\n");
var outline_f29_31_30197=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022892\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022894\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022893\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022898\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022899\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022901\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022896\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022897\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022902\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022903\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=related_link\">",
"      Enalapril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/18/32040?source=related_link\">",
"      Enalapril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30198="Diphtheria and tetanus toxoid: Pediatric drug information";
var content_f29_31_30198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphtheria and tetanus toxoid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10519?source=see_link\">",
"    see \"Diphtheria and tetanus toxoid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?10/30/10721?source=see_link\">",
"    see \"Diphtheria and tetanus toxoid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F161214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Decavac&reg; [DSC];",
"     </li>",
"     <li>",
"      Tenivac&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2934425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Td Adsorbed",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1057989\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vaccine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1057982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10519?source=see_link\">",
"      see \"Diphtheria and tetanus toxoid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Primary Immunization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children &ge;6 weeks to 7 years (prior to 7th birthday) with contraindication to immunization containing pertussis:",
"     <b>",
"      Note:",
"     </b>",
"     Preterm infants should be vaccinated according to their chronological age from birth; Pediatric formulation (DT): I.M.: 0.5 mL per dose for a total of 5 doses administered as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Three doses, usually given at 2-, 4-, and 6 months of age; may be given as early as 6 weeks of age and repeated every 4-8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Fourth dose: Given at ~15-18 months of age, but at least 6 months after third dose. The fourth dose may be given as early as 12 months of age, but at least 6 months must have elapsed between the third dose and the fourth dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Fifth dose: Given at 4-6 years of age, prior to starting school or kindergarten; if the fourth dose is given at &ge;4 years of age, the fifth dose may be omitted",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Infants and Children who start primary immunization series &ge;4 months of age through 6 years (prior to seventh birthday) (ACIP \"Catch-up Immunization Schedule): Pediatric formulation (DT): I.M.: 0.5 mL per dose, total of 4-5 doses administered as 3 doses at least 4 weeks apart followed 6 months later with dose 4; a fifth dose may be given 6 months later (the fifth dose is not necessary if the child received the fourth dose after 4 years of age)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;7 years, Adolescents, and Adults: Adult formulation (Td) (Teniva&trade;): I.M.: 0.5 mL per dose for a total of 3 doses. Patients previously not immunized should receive 2 primary doses of 0.5 mL each, given at an interval of 8 weeks; third (reinforcing) dose of 0.5 mL 6-8 months later",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Booster immunization:",
"     </b>",
"     For routine booster in patients who have completed primary immunization series. The ACIP prefers Tdap for use in in some situations if no contraindications exist; refer to Diphtheria and Tetanus Toxoids, and Acellular Pertussis Vaccine monograph for additional information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 11-12 years: I.M.: 0.5 mL as a single dose when at least 5 years have elapsed since last dose of toxoid-containing vaccine. Subsequent routine doses are not recommended more often than every 10 years.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents and Adults: I.M. 0.5 mL every 10 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tetanus prophylaxis in wound management:",
"     </b>",
"     Infants, Children, Adolescents, and Adults: Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Tetanus Prophylaxis Wound Management",
"     </caption>",
"     <col align=\"center\" width=\"250\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         History of Tetanus Immunization (Doses)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Clean, Minor Wounds",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         All Other Wounds",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &lt;7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years of age and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Yes, if &ge;10 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Yes, if &ge; 5 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Abbreviations:",
"         <b>",
"          DT",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years);",
"         <b>",
"          DTaP",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;);",
"         <b>",
"          Td",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Tenivac&trade;);",
"         <b>",
"          TT",
"         </b>",
"         = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]);",
"         <b>",
"          Tdap",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]);",
"         <b>",
"          TIG",
"         </b>",
"         = Tetanus Immune Globulin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from the Yellow Book 2010, Chapter 2,",
"         <i>",
"          Routine Vaccine-Preventable Diseases, Tetanus",
"         </i>",
"         ; Available at www.cdc.gov/yellowbook;  and",
"         <i>",
"          MMWR",
"         </i>",
"         , 2006, 55:RR-17.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Uncertain or &lt;3 doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         3 or more doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F161202\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [Td, adult; preservative free]: Diphtheria 2 Lf units and tetanus 2 Lf units per 0.5 mL (0.5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Decavac&reg; [DSC]: Diphtheria 2 Lf units and tetanus 5 Lf units per 0.5 mL (0.5 mL) [contains aluminum, may contain natural rubber/natural latex in prefilled syringe, thimerosal (may have trace amounts)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenivac&trade;: Diphtheria 2 Lf units and tetanus 5 Lf units per 0.5 mL (0.5 mL) [contains aluminum, may contain natural rubber/natural latex in prefilled syringe]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [DT, pediatric; preservative free]: Diphtheria 6.7 Lf units and tetanus 5 Lf units per 0.5 mL (0.5 mL) [DSC]; Diphtheria 25 Lf units and tetanus 5 Lf units per 0.5 mL (0.5 mL) [contains aluminum]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F161191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1057993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M. Prior to use, shake suspension well;",
"     <b>",
"      not for I.V. or SubQ administration",
"     </b>",
"     . Adolescents and adults should be vaccinated while seated or lying down:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     DT (pediatric use): Administer in either the anterolateral aspect of the thigh or arm; do not inject in the gluteal area",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Td: Administer in the deltoid muscle; do not inject in the gluteal area. Adolescents and adults should be vaccinated while seated or lying down.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     U.S. law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, and the administering person's name, title, and address be entered into the patient's permanent medical record.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1057985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F). Do not freeze; discard if product has been frozen.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1057992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diphtheria and tetanus toxoids adsorbed for pediatric use (DT): Active immunity against diphtheria and tetanus and tetanus prophylaxis in wound management when pertussis vaccine is contraindicated (FDA approved in ages &ge;6 weeks to &lt;7 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tetanus and diphtheria toxoids adsorbed for adult use (Td) (Decavac&reg;, Tenivac&trade;): Active immunity against diphtheria and tetanus; tetanus prophylaxis in wound management (FDA approved in ages &ge;7 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for the following:",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &bull; Children &ge;7 years, Adolescents, and Adults should receive a booster dose of Td every 10 years; may substitute a single Td booster dose with Tdap",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;text-align:justify;\">",
"     &bull; Children 7-10 years, Adolescents, Adults, and the Elderly (&ge;65 years) who are wounded in bombings or similar mass casualty events who have penetrating injuries or nonintact skin exposure and who cannot confirm receipt of a tetanus booster within the previous 5 years, may also receive a single dose of Td; children &ge;11 years, adolescents and adults may also receive Td if Tdap is unavailable",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7913819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diphtheria and Tetanus Toxoids (Td) may be confused with tuberculin purified protein derivative (PPD)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Pediatric diphtheria and tetanus (DT) may be confused with adult tetanus and diphtheria (Td)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F161231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, tiredness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Lymph node swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Local: Injection site: Erythema, pain, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Body ache/muscle weakness, sore/swollen joints",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Allergic reactions (angioedema, rash, urticaria), anaphylactic reactions, arthralgia, chills, dizziness, fatigue, injection site reactions (cellulitis, induration, nodules, warmth), lymphadenopathy, musculoskeletal stiffness, myalgia, pain, pain in extremities, paresthesia, peripheral edema, seizure, syncope, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1057995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphtheria, tetanus toxoid, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1057981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Immunization should be delayed during the course of an acute severe febrile illness; may administer to patients with mild acute illness (with or without fever). Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy, including high-dose corticosteroids); may have a reduced response to vaccination and vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval (CDC, 2011). In general, household and close contacts of persons with altered immunocompetence may receive all age-appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; if the patient receives antihemophilia or other similar therapy, I.M. injection can be scheduled shortly after such therapy is administered. Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1057980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diphtheria and tetanus toxoid is available in two formulations which contain different amounts of the diphtheria toxoid; DT or &ldquo;pediatric&rdquo; formulation has twice the diphtheria toxoid as Td or &ldquo;adult&rdquo; toxoid; use of DT in children &gt;7 years and adults is associated with more severe adverse reactions to the diphtheria toxoid than in infants and younger children. Immediate treatment for anaphylactic/anaphylactoid reaction should be available during administration of these vaccines. Patients with a history of severe local reaction (Arthus-type) or temperature of &gt;39.4&deg;C (103&deg;F) following a previous dose should not be given further routine or emergency doses of Td more frequently than every 10 years. Guillain-Barr&eacute; syndrome, occurring within 6 weeks of tetanus toxoid vaccination, has been reported. Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs. Some products may contain natural latex/natural rubber; use with caution in patients who may be susceptible to hypersensitivity reactions. Some products may contain thimerosal.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299214\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F161197\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F161199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F161210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. DT is not recommended for use in persons &ge;7 years of age. Inactivated bacterial vaccines have not been shown to cause increased risks to the fetus (CDC, 60[2], 2011). The Advisory Committee on Immunization Practices (ACIP) recommends booster injections for previously vaccinated pregnant women who have not had Td vaccination within the past 10 years. Pregnant women who are not immunized or are only partially immunized should complete the primary series. Vaccination may be deferred until the postpartum period in women who are likely to have sufficient diphtheria and tetanus protection until delivery; Tdap may be substituted for Td after delivery to add extra protection against pertussis. Td should be administered during pregnancy to women who do not have sufficient tetanus immunity to protect against maternal and neonatal tetanus, and if booster protection for diphtheria is required (eg, travel to where diphtheria is endemic). Tetanus immune globulin and a tetanus toxoid containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women; the use of Td during pregnancy is recommended for wound management if &ge;5 years have passed since the last Td vaccination.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13925099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Observe for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1057987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/30/10721?source=see_link\">",
"      see \"Diphtheria and tetanus toxoid: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May experience mild fever or soreness, swelling, and redness/knot at the injection site usually lasting 1-2 days",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F10278557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;margin-top:0em;display:inline\">",
"     In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single visit, unless contraindications exist. If available, the use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. If separate vaccines being used, evaluate product information regarding same syringe compatibility of vaccines. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of specific vaccine in a series come from the same manufacturer if possible (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     For additional information, please refer to the following website:",
"     <a href=\"file://www.cdc.gov/vaccines/vpd-vac/\" target=\"_blank\">",
"      file://www.cdc.gov/vaccines/vpd-vac/",
"     </a>",
"     .",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      AAP Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, \"Febrile Seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"FDA Approval of Expanded Age Indication for a Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2009, 58(14):374-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/19373199/pubmed\" id=\"19373199\" target=\"_blank\">",
"        19373199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-3):1-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/16557217/pubmed\" id=\"16557217\" target=\"_blank\">",
"        16557217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Preventing Tetanus, Diphtheria, and Pertussis Among Adults: Use of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Recommendations of the Advisory Committee on Immunization Practices (ACIP) and Recommendation of ACIP, Supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for Use of Tdap Among Health-Care Personnel,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2006, 55(RR-17):1-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/17167397/pubmed\" id=\"17167397\" target=\"_blank\">",
"        17167397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants,  Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-4):1-51; published erratum appears in",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 57(26):723.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/18509304/pubmed\" id=\"18509304\" target=\"_blank\">",
"        18509304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human  Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events-United States, 2008: Recommendations of the Centers For Disease Control And Prevention (CDC),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-6):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/18668022/pubmed\" id=\"18668022\" target=\"_blank\">",
"        18668022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Syncope After Vaccination-United States, January 2005-July 2007,\"",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2008, 2;57(17):457-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/18451756/pubmed\" id=\"18451756\" target=\"_blank\">",
"        18451756",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, \"Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30198/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12712 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-5A6B11C91F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30198=[""].join("\n");
var outline_f29_31_30198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161214\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934425\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057989\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057982\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161202\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161191\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057993\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057985\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057992\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7913819\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161231\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057995\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057981\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057980\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299214\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161197\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161199\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F161210\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13925099\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1057987\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10278557\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12712\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12712|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10519?source=related_link\">",
"      Diphtheria and tetanus toxoid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?10/30/10721?source=related_link\">",
"      Diphtheria and tetanus toxoid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30199="Beclomethasone (oral inhalation): Drug information";
var content_f29_31_30199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Beclomethasone (oral inhalation): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?26/17/26901?source=see_link\">",
"    see \"Beclomethasone (oral inhalation): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/13/44245?source=see_link\">",
"    see \"Beclomethasone (oral inhalation): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7990266\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      QVAR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F7990267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      QVAR&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7990252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Inhalant (Oral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7991795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Inhalation, oral (doses should be titrated to the lowest effective dose once asthma is controlled):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients previously on bronchodilators only: Initial dose 40-80 mcg twice daily; maximum dose: 320 mcg twice day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients previously on inhaled corticosteroids: Initial dose 40-160 mcg twice daily; maximum dose: 320 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NIH Asthma Guidelines (NIH, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 80-240 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;240-480 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;480 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild asthma: 50-100 mcg twice daily; maximum dose: 100 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate asthma: 100-250 mcg twice daily; maximum dose: 250 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe asthma: 300-400 mcg twice daily; maximum dose: 400 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:",
"     </b>",
"     Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than &le;2.5 mg/day (or equivalent of other OCS) every 1-2 weeks. The Canadian labeling recommends decreasing the daily dose of prednisone by 1 mg (or equivalent of other OCS) every 7 days or more in closely monitored patients. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal.",
"     <b>",
"      Note:",
"     </b>",
"     When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F7991794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/13/44245?source=see_link\">",
"      see \"Beclomethasone (oral inhalation): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Asthma:",
"     </b>",
"     Inhalation, oral (doses should be titrated to the lowest effective dose once asthma is controlled):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      U.S. labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-11 years: Initial: 40 mcg twice daily; maximum dose: 80 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      NIH Asthma Guidelines",
"     </i>",
"     (NIH, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children 5-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Low&rdquo; dose: 80-160 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;Medium&rdquo; dose: &gt;160-320 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     &ldquo;High&rdquo; dose: &gt;320 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Canadian labeling:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 5-11 years: Initial: 50 mcg twice daily; maximum dose: 100 mcg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years and Adults: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Conversion from oral systemic corticosteroid to orally inhaled corticosteroid:",
"     </b>",
"     Initiation of oral inhalation therapy should begin in patients whose asthma is reasonably stabilized on oral corticosteroids (OCS). A gradual dose reduction of OCS should begin ~7 days after starting inhaled therapy. U.S. labeling recommends reducing prednisone dose no more rapidly than &le;2.5 mg/day (or equivalent of other OCS) every 1-2 weeks. The Canadian labeling recommends decreasing the daily dose of prednisone by 1 mg (or equivalent of other OCS) every 7 days or more in closely monitored patients. If adrenal insufficiency occurs, temporarily increase the OCS dose and follow with a more gradual withdrawal.",
"     <b>",
"      Note:",
"     </b>",
"     When transitioning from systemic to inhaled corticosteroids, supplemental systemic corticosteroid therapy may be necessary during periods of stress or during severe asthma attacks.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7991796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7991812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as dipropionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 40 mcg/inhalation (7.3 g [DSC]) [chlorofluorocarbon free; contains ethanol; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 40 mcg/inhalation (8.7 g) [chlorofluorocarbon free; contains ethanol; 120 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 80 mcg/inhalation (7.3 g [DSC]) [chlorofluorocarbon free; contains ethanol; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&reg;: 80 mcg/inhalation (8.7 g) [chlorofluorocarbon free; contains ethanol; 120 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F14291437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Aerosol, for oral inhalation, as dipropionate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&trade;: 50 mcg/inhalation (6.5 g) [chlorofluorocarbon free; contains ethanol; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&trade;: 50 mcg/inhalation (12.4 g) [chlorofluorocarbon free; contains ethanol; 200 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&trade;: 100 mcg/inhalation (6.5 g) [chlorofluorocarbon free; contains ethanol; 100 metered actuations]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     QVAR&trade;: 100 mcg/inhalation (12.4 g) [chlorofluorocarbon free; contains ethanol; 200 metered actuations]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7990269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7991798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Canister does not need shaken prior to use. Prime canister by spraying twice into the air prior to initial use or if not in use for &gt;10 days. Avoid spraying in face or eyes. Exhale fully prior to bringing inhaler to mouth. Place inhaler in mouth, close lips around mouthpiece, and inhale slowly and deeply. Remove inhaler and hold breath for approximately 5-10 seconds. Rinse mouth and throat after use to prevent",
"     <i>",
"      Candida",
"     </i>",
"     infection. Do not wash or put inhaler in water; mouth piece may be cleaned with a dry tissue or cloth. Discard after the \"discard by\" date or after labeled number of doses has been used, even if container is not completely empty.  Patients using a spacer should inhale immediately due to decreased amount of medication that is delivered with a delayed inspiration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7990270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral inhalation: Maintenance and prophylactic treatment of asthma; includes those who require corticosteroids and those who may benefit from a dose reduction/elimination of systemically-administered corticosteroids. Not for relief of acute bronchospasm.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7991730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dysphonia (1% to 3%), pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (9%), pharyngitis (8%), rhinitis (6%), sinusitis (3%), cough (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactic/anaphylactoid reactions; growth velocity reduction in children/adolescents; HPA function suppression; immediate and delayed hypersensitivity reactions (angioedema, bronchospasm, rash, urticaria); psychiatric and behavioral changes (such as aggressiveness, depression, sleep disturbances, psychomotor hyperactivity, suicidal ideation; more common in children); rarely glaucoma, increased intraocular pressure, and cataracts have been reported with inhaled corticosteroids",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7991662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to beclomethasone or any component of the formulation; status asthmaticus, or other acute asthma episodes requiring intensive measures",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Moderate-to-severe bronchiectasis requiring intensive measures; untreated fungal, bacterial, or tubercular infections of the respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7991683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bronchospasm: May occur with wheezing after inhalation; if this occurs, stop steroid and treat with a fast-acting bronchodilator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use in patients with ocular herpes or untreated viral, fungal, parasitic or bacterial systemic infections (Canadian labeling contraindicates use with untreated respiratory infections). Exposure to chickenpox should be avoided. Close observation is required in patients with latent tuberculosis and/or TB reactivity; restrict use in active TB (only in conjunction with antituberculosis treatment).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular events: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, glaucoma, and cataracts have occurred (rarely) with oral inhalation of corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Supplemental steroids (oral or parenteral) may be needed during stress or severe asthma attacks. Not to be used in status asthmaticus or for the relief of acute bronchospasm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarct (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Orally-inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range: 0.3-1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally-inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients. Safety and efficacy  have not been established in children &lt;5 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw systemic therapy with gradual tapering of dose. There have been reports of systemic corticosteroid withdrawal symptoms (eg, joint/muscle pain, lassitude, depression) when withdrawing oral inhalation therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7991733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Orally Inhaled) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Orally Inhaled) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7991657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7991658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies following SubQ administration but not with oral inhalation. A decrease in fetal growth has not been observed with inhaled corticosteroid use during pregnancy. Inhaled corticosteroids are recommended for the treatment of asthma (most information available using budesonide) during pregnancy (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7991660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7991661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Other corticosteroids have been found in breast milk; however, information for beclomethasone is not available. Use of inhaled corticosteroids is not a contraindication to breast-feeding (NAEPP, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F7991814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Aerosol solution",
"     </b>",
"     (Qvar Inhalation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mcg/ACT (8.7 g): $134.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mcg/ACT (8.7 g): $179.62",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14291422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth (adolescents) and signs/symptoms of HPA axis suppression/adrenal insufficiency; signs/symptoms of oral candidiasis; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      AeroBec (DK, NO, SE);",
"     </li>",
"     <li>",
"      Aerocort (MY);",
"     </li>",
"     <li>",
"      Aerovent (IN);",
"     </li>",
"     <li>",
"      Asmabec Clickhaler (FR, IE);",
"     </li>",
"     <li>",
"      Beclate (ZA);",
"     </li>",
"     <li>",
"      Beclazone (HK, NZ);",
"     </li>",
"     <li>",
"      Beclomet (DK, FI, NO, SE, SG, TH);",
"     </li>",
"     <li>",
"      Beclomin (PK);",
"     </li>",
"     <li>",
"      Beclone (FR);",
"     </li>",
"     <li>",
"      Beclophar (GB, IE);",
"     </li>",
"     <li>",
"      Beclovent Inhalador (CO);",
"     </li>",
"     <li>",
"      Beconase (VE);",
"     </li>",
"     <li>",
"      Becotide (CH, CL, CR, CZ, DO, GT, HN, IE, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bemedrex (FR);",
"     </li>",
"     <li>",
"      Bronconox (CO);",
"     </li>",
"     <li>",
"      Bronconox Forte (CO);",
"     </li>",
"     <li>",
"      Clenil (BR, IT, SG, TW);",
"     </li>",
"     <li>",
"      Destap SF (CN);",
"     </li>",
"     <li>",
"      Eclosynt (CO);",
"     </li>",
"     <li>",
"      Ecobec (BG, EE, PT);",
"     </li>",
"     <li>",
"      Propavent (AR);",
"     </li>",
"     <li>",
"      Qvar (AU, CH, CR, DO, FR, GB, GT, HN, IE, IL, MY, NI, NZ, PA, PT, SV, TH);",
"     </li>",
"     <li>",
"      Respocort (NZ);",
"     </li>",
"     <li>",
"      Ventolair (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7991739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis; depresses the migration of polymorphonuclear leukocytes, fibroblasts; reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7991741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic effect: 1-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Readily; quickly hydrolyzed by pulmonary esterases to active metabolite (beclomethasone-17-monoproprionate [17-BMP]) during absorption",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 17-BMP: 94% to 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Pro-drug; undergoes rapid conversion to 17-BMP during absorption; followed by additional metabolism via CYP3A4 to other, less active metabolites (beclomethasone-21-monopropionate [21-BMP] and beclomethasone [BOH])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 17-BMP: 3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: Oral inhalation: BDP: 0.5 hours; 17-BMP: 0.7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Mainly in feces; urine (&lt;10%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bakhireva LN, Jones KL, Schatz M, et al, &ldquo;Asthma Medication Use in Pregnancy and fetal Growth,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2005, 116(3):503-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/16159616/pubmed\" id=\"16159616\" target=\"_blank\">",
"        16159616",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Namazy J, Schatz M, Long L, et al, &ldquo;Use of Inhaled Steroids by Pregnant Asthmatic Women Does Not Reduce Intrauterine Growth,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2004, 113(3):427-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/15007341/pubmed\" id=\"15007341\" target=\"_blank\">",
"        15007341",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;NAEPP Expert Panel Report. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment - 2004 Update,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 2005, 115(1):34-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/15637545/pubmed\" id=\"15637545\" target=\"_blank\">",
"        15637545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tinkelman DG, Reed CE, Nelson HS, et al, &ldquo;Aerosol Beclomethasone Dipropionate Compared With Theophylline as Primary Treatment of Chronic, Mild-to-Moderately Severe Asthma in Children,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1993, 92(1):64-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/8516087/pubmed\" id=\"8516087\" target=\"_blank\">",
"        8516087",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Buck JJ, et al, &ldquo;Acute Adrenal Crisis in Asthmatics Treated With High-Dose Fluticasone Propionate,&rdquo;",
"      <i>",
"       Eur Respir J",
"      </i>",
"      , 2002, 19(6):1207-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/12108877/pubmed\" id=\"12108877\" target=\"_blank\">",
"        12108877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Todd GR, Acerini CL, Ross-Russell R, et al, &ldquo;Survey of Adrenal Crisis Associated With Inhaled Corticosteroids in the United Kingdom,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 2002, 87(6):457-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/12456538/pubmed\" id=\"12456538\" target=\"_blank\">",
"        12456538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wyatt R, Waschek J, Weinberger M, et al, &ldquo;Effects of Inhaled Beclomethasone Dipropionate and Alternate-Day Prednisone on Pituitary-Adrenal Function in Children With Chronic Asthma,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1978, 299(25):1387-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30199/abstract-text/362207/pubmed\" id=\"362207\" target=\"_blank\">",
"        362207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8876 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-58.240.98.179-1360C6F796-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30199=[""].join("\n");
var outline_f29_31_30199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990266\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990267\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990252\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991795\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991794\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991796\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991812\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14291437\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990269\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991798\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7990270\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991730\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991662\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991683\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298819\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991733\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991657\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991658\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991660\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991661\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991814\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14291422\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961956\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991739\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7991741\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8876\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8876|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/39/21109?source=related_link\">",
"      Beclomethasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?15/51/16180?source=related_link\">",
"      Beclomethasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/34/7716?source=related_link\">",
"      Beclomethasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?26/17/26901?source=related_link\">",
"      Beclomethasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/13/44245?source=related_link\">",
"      Beclomethasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30200="Theophylline: Drug information";
var content_f29_31_30200=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Theophylline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/7/1141?source=see_link\">",
"    see \"Theophylline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"    see \"Theophylline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elixophyllin&reg; Elixir;",
"     </li>",
"     <li>",
"      Theo-24&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Theo LA&reg;;",
"     </li>",
"     <li>",
"      Novo-Theophyl SR;",
"     </li>",
"     <li>",
"      PMS-Theophylline;",
"     </li>",
"     <li>",
"      Pulmophylline;",
"     </li>",
"     <li>",
"      ratio-Theo-Bronc;",
"     </li>",
"     <li>",
"      Teva-Theophylline SR;",
"     </li>",
"     <li>",
"      Theo ER;",
"     </li>",
"     <li>",
"      Theolair;",
"     </li>",
"     <li>",
"      Uniphyl",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F226601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Phosphodiesterase Enzyme Inhibitor, Nonselective",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F226557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be individualized based on steady-state serum concentrations and ideal body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Acute symptoms: Loading dose:",
"      </i>",
"     </b>",
"     Oral, I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Asthma exacerbations:",
"     </i>",
"     While theophylline may be considered for relief of asthma symptoms, the role of treating exacerbations is not supported by current practice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      COPD treatment:",
"     </i>",
"     Theophylline is currently considered second-line intravenous therapy in the emergency department or hospital setting when there is inadequate or insufficient response to short acting bronchodilators (Global Initiative for COPD Guidelines, 2013).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      If no theophylline received within the previous 24 hours:",
"     </b>",
"     4.6 mg/kg loading dose (~5.8 mg/kg hydrous aminophylline) I.V. or 5 mg/kg orally. Loading dose intended to achieve a serum level of approximately 10 mcg/mL; loading doses should be given intravenously (preferred) or with a rapidly absorbed oral product (not an extended-release product).",
"     <b>",
"      Note:",
"     </b>",
"     On the average, for every 1 mg/kg theophylline given, blood levels will rise 2 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      If theophylline has been administered in the previous 24 hours:",
"     </b>",
"     A loading dose is not recommended without obtaining a serum theophylline concentration. The loading dose should be calculated as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V",
"     <sub>",
"      d",
"     </sub>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute symptoms: Maintenance dose:",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     To achieve a target concentration of 10 mcg/mL unless otherwise noted. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements during the first 12- to 24-hour period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults 16-60 years (otherwise healthy, nonsmokers): 0.4 mg/kg/hour; maximum: 900 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adults &gt;60 years: 0.3 mg/kg/hour; maximum: 400 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment of chronic conditions:",
"      </i>",
"     </b>",
"     With newer guidelines suggesting lower therapeutic theophylline ranges, it is unlikely that doses larger than &gt;10 mg/kg/day will be required in children &ge;1 year of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Oral solution:",
"     </i>",
"     Initial dose: 300 mg/day administered in divided doses every 6-8 hours; Maintenance: 400-600 mg/day (maximum: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Oral extended release formulations:",
"     </i>",
"     Initial dose: 300-400 mg once daily; Maintenance: 400-600 mg once daily (maximum: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment after serum theophylline measurement:",
"      </i>",
"     </b>",
"     Asthma: Within normal limits: Adults: 5-15 mcg/mL: Maintain dosage if tolerated. Recheck serum theophylline concentration at 24-hour intervals (for acute I.V. dosing) or at 6- to 12-month intervals (for oral dosing). Finer adjustments in dosage may be needed for some patients. If levels &ge;15 mcg/mL, consider 10% dose reduction to improve safety margin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Recheck serum theophylline levels after 3 days when using oral dosing, or after 12 hours (children) or 24 hours (adults) when dosing intravenously. Patients maintained with oral therapy may be reassessed at 6- to 12-month intervals.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F226578\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=see_link\">",
"      see \"Theophylline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be individualized based on steady-state serum concentrations and ideal body weight.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Acute symptoms: Loading dose:",
"      </i>",
"     </b>",
"     Oral, I.V.: Asthma exacerbations: While theophylline may be considered for relief of asthma symptoms, the role of treating exacerbations is not supported by current practice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      If no theophylline received within the previous 24 hours:",
"     </b>",
"     4.6 mg/kg loading dose (~5.8 mg/kg hydrous aminophylline) I.V. or 5 mg/kg orally. Loading dose intended to achieve a serum level of approximately 10 mcg/mL; loading doses should be given intravenously (preferred) or with a rapidly absorbed oral product (not an extended-release product).",
"     <b>",
"      Note:",
"     </b>",
"     On the average, for every 1 mg/kg theophylline given, blood levels will rise 2 mcg/mL.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      If theophylline has been administered in the previous 24 hours:",
"     </b>",
"     A loading dose is not recommended without obtaining a serum theophylline concentration. The loading dose should be calculated as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Dose = (desired serum theophylline concentration - measured serum theophylline concentration) (V",
"     <sub>",
"      d",
"     </sub>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Acute symptoms: Maintenance dose:",
"      </i>",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     To achieve a target concentration of 10 mcg/mL unless otherwise noted. Lower initial doses may be required in patients with reduced theophylline clearance. Dosage should be adjusted according to serum level measurements during the first 12- to 24-hour period.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Infants 6-52 weeks: mg/kg/hour = (0.008) (age in weeks) + 0.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 1-9 years: 0.8 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Children 9-12 years: 0.7 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adolescents 12-16 years (cigarette or marijuana smokers): 0.7 mg/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Adolescents 12-16 years (nonsmokers): 0.5 mg/kg/hour; maximum: 900 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Treatment of chronic conditions:",
"      </i>",
"     </b>",
"     With newer guidelines suggesting lower therapeutic theophylline ranges, it is unlikely that doses larger than &gt;10 mg/kg/day will be required in children &ge;1 year of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Oral solution:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Infants &lt;1 year:",
"     <b>",
"      Note:",
"     </b>",
"     Doses should be adjusted to maintain the peak steady state serum concentrations. The time to reach steady state will vary based on age and the presence of risk factors which may affect theophylline clearance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Full-term Infants and Infants &lt;26 weeks: Total daily dose (mg)= [(0.2 x age in weeks) +5] x (weight in kg); divide dose into 3 equal amounts and administer at 8-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Full-term Infants and Infants &ge;26 weeks and &lt;52 weeks: Total daily dose (mg) = [(0.2 x age in weeks) +5] x (weight in kg); divide dose into 4 equal amounts and administer at 6-hour intervals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;1 year and &lt;45 kg: Initial dose: 10-14 mg/kg/day (maximum: 300 mg/day) administered in divided doses every 4-6 hours; Maintenance: Up to 20 mg/kg/day (maximum: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &gt;45 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Oral extended release formulations:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &ge;1 year  and &lt;45 kg: Initial: 10-14 mg/kg once daily (maximum: 300 mg/day); Maintenance up to 20 mg/kg/day (maximum: 600 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Children &gt;45 kg: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage adjustment after serum theophylline measurement:",
"      </i>",
"     </b>",
"     Asthma: Within normal limits: Children: 5-10 mcg/mL: Maintain dosage if tolerated. Recheck serum theophylline concentration at 24-hour intervals (for acute I.V. dosing) or at 6- to 12-month intervals (for oral dosing). Finer adjustments in dosage may be needed for some patients. If levels &ge;15 mcg/mL, consider 10% dose reduction to improve safety margin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Recheck serum theophylline levels after 3 days when using oral dosing, or after 12 hours (children) or 24 hours (adults) when dosing intravenously. Patients maintained with oral therapy may be reassessed at 6- to 12-month intervals.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F226558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acute symptoms:  Adults &gt;60 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Loading dose: Oral, I.V.: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Maintenance dose: I.V.: 0.3 mg/kg/hour; maximum 400 mg/day unless serum levels indicate need for larger dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Chronic conditions: Oral: Adults &gt;60 years: Do not exceed a dose of 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiac decompensation, cor pulmonale, hepatic dysfunction, sepsis with multiorgan failure, shock: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Theo-24&reg;: 100 mg, 200 mg, 300 mg, 400 mg [24 hours]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 400 mg (500 mL); 800 mg (500 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 80 mg/15 mL (15 mL, 473 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elixophyllin&reg; Elixir: 80 mg/15 mL (473 mL) [contains ethanol 20%; mixed fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 100 mg, 200 mg, 300 mg, 400 mg, 450 mg, 600 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Extended release tablet, infusion, solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F226529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Administer loading dose over 30 minutes; follow with a continuous infusion as appropriate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Long-acting preparations should be taken with a full glass of water, swallowed whole, or cut in half if scored. Do",
"     <b>",
"      not",
"     </b>",
"     crush. Extended release capsule forms may be opened and the contents sprinkled on soft foods; do",
"     <b>",
"      not",
"     </b>",
"     chew beads.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F226605\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, ampicillin, ampicillin/sulbactam, aztreonam, bivalirudin, cefazolin, cefotetan, ceftriaxone, cimetidine, cisatracurium, clindamycin, clonidine, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, dobutamine, dopamine, doxycycline, erythromycin lactobionate, famotidine, fenoldopam, fentanyl, fluconazole, gentamicin, haloperidol, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, lidocaine, linezolid, methyldopate, methylprednisolone sodium succinate, metronidazole, micafungin, midazolam, milrinone, nafcillin, nitroglycerin, nitroprusside, oxaliplatin, penicillin G potassium, piperacillin, potassium chloride, ranitidine, remifentanil, ticarcillin/clavulanate potassium, tigecycline, tobramycin, vancomycin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Cefepime, hetastarch in NS, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Ceftazidime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F226528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of symptoms and reversible airway obstruction due to chronic asthma, or other chronic lung diseases",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     The Global Initiative for Asthma Guidelines (2009) and the National Heart, Lung and Blood Institute Guidelines (2007) do not recommend oral theophylline as a long-term control medication for asthma in children &le;5 years of age; use has been shown to be effective as an add-on (but not preferred) agent in older children and adults with severe asthma treated with inhaled or oral glucocorticoids. The guidelines do not recommend theophylline for the treatment of exacerbations of asthma.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Global Initiative for Chronic Obstructive Lung Disease Guidelines (2013) suggest that while higher doses of slow release formulations of theophylline have been proven to be effective for use in COPD, it is not a preferred agent due to its potential for toxicity.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F226599\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined. Adverse events observed at therapeutic serum levels:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Flutter, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Central nervous system: Headache, hyperactivity (children), insomnia, restlessness, seizures, status epilepticus (nonconvulsive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Endocrine &amp; metabolic: Hypercalcemia (with concomitant hyperthyroid disease)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Nausea, reflux or ulcer aggravation, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Difficulty urinating (elderly males with prostatism)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular &amp; skeletal: Tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Renal: Diuresis (transient)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F226532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to theophylline or any component of the formulation; premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn-related products",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F226515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Central nervous system: Theophylline-induced nonconvulsive status epilepticus has been reported (rarely) and should be considered in patients who develop CNS abnormalities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Theophylline toxicity: If a patient develops signs and symptoms of theophylline toxicity (eg, persistent, repetitive vomiting), a serum level should be measured and subsequent doses held. Theophylline clearance may be decreased in patients with acute pulmonary edema, congestive heart failure, cor pulmonale, fever, hepatic disease, acute hepatitis, cirrhosis, hypothyroidism, sepsis with multiorgan failure, and shock; clearance may also be decreased in neonates, infants &lt;3 months of age with decreased renal function, children &lt;1 year of age, the elderly &gt;60 years of age, and patients following cessation of smoking.",
"     <b>",
"      Note:",
"     </b>",
"     Elderly &gt;75 years of age have a 16-fold greater risk of death from theophylline overdose than do 25-year-olds due to reduced clearance in the elderly patient.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with tachyarrhythmias (eg, sinus tachycardia, atrial fibrillation) since use may exacerbate these arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; use may exacerbate this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peptic ulcer disease: Use with caution in patient with peptic ulcer disease; use may exacerbate this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; use may exacerbate this condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Monitoring: Frequent continued monitoring of serum theophylline after therapeutic levels have been achieved may not be required as long as there is no apparent risk of decreased theophylline metabolism due to concurrent drug therapies or disease states. Monitoring serum theophylline concentrations at yearly intervals should be adequate in such cases.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F226596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adalimumab: May decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adenosine: Theophylline Derivatives may diminish the therapeutic effect of Adenosine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antithyroid Agents: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: Theophylline Derivatives may diminish the therapeutic effect of Benzodiazepines.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Theophylline Derivatives. Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Theophylline Derivatives may decrease the serum concentration of CarBAMazepine. CarBAMazepine may decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Moderate): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inhibitors (Strong): May decrease the metabolism of CYP1A2 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP2E1 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of Theophylline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disulfiram: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Febuxostat: May increase serum concentrations of the active metabolite(s) of Theophylline Derivatives. Specifically, concentrations of 1-methylxanthine, a metabolite of unknown clinical importance, may become elevated. Management: The U.S. febuxostat labeling recommends using caution in patients receiving concomitant theophylline due to risks of increased theophylline metabolite exposure. The Canadian febuxostat labeling contraindicates its use with theophylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FluvoxaMINE: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Formoterol: Theophylline Derivatives may enhance the adverse/toxic effect of Formoterol. Theophylline Derivatives may enhance the hypokalemic effect of Formoterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Theophylline Derivatives may decrease the serum concentration of Fosphenytoin. Fosphenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: Theophylline Derivatives may enhance the adverse/toxic effect of Indacaterol. Theophylline Derivatives may enhance the hypokalemic effect of Indacaterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Interferons: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoproterenol: May decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Theophylline Derivatives may decrease the serum concentration of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin; Telithromycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mexiletine: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancuronium: Theophylline Derivatives may enhance the adverse/toxic effect of Pancuronium. Theophylline Derivatives may diminish the neuromuscular-blocking effect of Pancuronium.  Management: Pancuronium dosage adjustment may be necessary to induce paralysis  in patients receiving concomitant theophylline derivatives. Monitor closely for adverse effects (e.g., cardiac effects) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Theophylline Derivatives may decrease the serum concentration of Phenytoin. Phenytoin may decrease the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Fosamprenavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNINE: May increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May decrease the metabolism of Theophylline Derivatives. Ciprofloxacin and enoxacin are of greatest concern.  Theophylline/quinolone therapy might augment the seizure-producing potential of each of the individual agents.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Gemifloxacin; Levofloxacin (Systemic); Lomefloxacin; Moxifloxacin (Systemic); Nalidixic Acid; Sparfloxacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regadenoson: Theophylline may diminish the vasodilatory effect of Regadenoson.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiabendazole: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thyroid Products: May increase the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticlopidine: May decrease the metabolism of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zafirlukast: Theophylline Derivatives may decrease the serum concentration of Zafirlukast. Zafirlukast may increase the serum concentration of Theophylline Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zileuton: May increase the serum concentration of Theophylline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F226548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Food does not appreciably affect the absorption of liquid, fast-release products, and most sustained release products; however, food may induce a sudden release (dose-dumping) of once-daily sustained release products resulting in an increase in serum drug levels and potential toxicity. Changes in diet may affect the elimination of theophylline; charbroiled foods may increase elimination, reducing half-life by 50%. Management: Should be taken with water 1 hour before or 2 hours after meals. Avoid excessive amounts of caffeine. Avoid extremes of dietary protein and carbohydrate intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F226536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were observed in animal reproduction studies. Theophylline crosses the placenta; adverse effects may be seen in the newborn. Use is generally safe when used at the recommended doses (serum concentrations 5-12 mcg/mL) however maternal adverse events may be increased and efficacy may be decreased in pregnant women. Theophylline metabolism may change during pregnancy; the half-life is similar to that observed in otherwise healthy, nonsmoking adults with asthma during the first and second trimesters (~8.7 hours), but may increase to 13 hours (range: 8-18 hours) during the third trimester. The volume of distribution is also increased during the third trimester. Monitor serum levels. The recommendations for the use of theophylline in pregnant women with asthma are similar to those used in nonpregnant adults (National Heart, Lung, and Blood Institute Guidelines, 2004).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F226562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/compatible (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F226537\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The concentration of theophylline in breast milk is similar to the maternal serum concentration. Irritability may be observed in the nursing infant. Serious adverse events in the infant are unlikely unless toxic serum levels are present in the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F226538\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with water 1 hour before or 2 hours after meals. Premixed injection may contain corn-derived dextrose and its use is contraindicated in patients with allergy to corn-related products.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F226535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Theo-24 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $135.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $201.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $247.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $348.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Elixir",
"     </b>",
"     (Elixophyllin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/15 mL (473 mL): $91.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Theophylline in D5W Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.8 mg/mL 5% (500 mL): $5.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.6 mg/mL 5% (250 mL): $6.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Theophylline Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg/15 mL (473 mL): $111.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Theochron Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $23.05",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $36.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $60.48",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Theophylline ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $23.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $36.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $51.11",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     450 mg (100): $68.27",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Theophylline ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (100): $135.76",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     600 mg (100): $196.17",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6871829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor heart rate, CNS effects (insomnia, irritability); respiratory rate (COPD patients often have resting controlled respiratory rates in low 20s); arterial or capillary blood gases (if applicable)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline levels: Serum theophylline levels should be monitored prior to making dose increases; in the presence of signs or symptoms of toxicity; or when a new illness, worsening of a present illness, or medication changes occur that may change theophylline clearance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. loading dose: Measure serum concentrations 30 minutes after the end of an I.V. loading dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V. infusion: Measure serum concentrations one half-life after starting a continuous infusion, then every 12-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F6871828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic levels:  Asthma:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children: 5-10 mcg/mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults: 5-15 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F226539\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aerobin (DE);",
"     </li>",
"     <li>",
"      Austyn (KP);",
"     </li>",
"     <li>",
"      Bronchoretard (DE);",
"     </li>",
"     <li>",
"      Bronsolvan (ID);",
"     </li>",
"     <li>",
"      Bufabron (ID);",
"     </li>",
"     <li>",
"      Ditenaten (DE);",
"     </li>",
"     <li>",
"      Duralyn-CR (TH);",
"     </li>",
"     <li>",
"      Egifilin (HU);",
"     </li>",
"     <li>",
"      Elixine (CN);",
"     </li>",
"     <li>",
"      Eteophyl (KP);",
"     </li>",
"     <li>",
"      Etipramid (CL);",
"     </li>",
"     <li>",
"      Euphyllin (PL);",
"     </li>",
"     <li>",
"      Euphyllin Retard (ID, TW);",
"     </li>",
"     <li>",
"      Euphyllin Retard Mite (ID);",
"     </li>",
"     <li>",
"      Euphylong (AE, BH, CY, EG, HK, HU, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Euphylong Retardkaps (DE);",
"     </li>",
"     <li>",
"      Lasma (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Meridian AP (UY);",
"     </li>",
"     <li>",
"      Nefoben (AR);",
"     </li>",
"     <li>",
"      Neulin-SR (NZ, TW);",
"     </li>",
"     <li>",
"      Nosma (TW);",
"     </li>",
"     <li>",
"      Nuelin (AU, BB, BM, BS, BZ, DK, FI, GY, JM, NO, NZ, PH, PR, SG, SR, TT, VE);",
"     </li>",
"     <li>",
"      Nuelin SA (AE, BF, BH, BJ, CI, CR, CY, EG, ET, GH, GM, GN, IE, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PA, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nuelin SR (AE, AU, BH, CY, EG, HK, IQ, IR, JO, KW, LB, LY, MY, OM, QA, SA, SG, SY, TH, YE);",
"     </li>",
"     <li>",
"      Pediaphyllin PL (LU);",
"     </li>",
"     <li>",
"      Pharmafil (MX);",
"     </li>",
"     <li>",
"      Phylobid (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Quibron T SR (ID);",
"     </li>",
"     <li>",
"      Retafyllin (EE, HU);",
"     </li>",
"     <li>",
"      Slo-Phyllin (AE, BH, CY, EG, GB, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Slo-Theo (HK);",
"     </li>",
"     <li>",
"      Solosin (DE);",
"     </li>",
"     <li>",
"      Somofillina (IT);",
"     </li>",
"     <li>",
"      Talofilina (BR);",
"     </li>",
"     <li>",
"      Teoclear (KP);",
"     </li>",
"     <li>",
"      Teoclear LA (AR);",
"     </li>",
"     <li>",
"      Teofilina Retard (CO, EC);",
"     </li>",
"     <li>",
"      Teolin (HR);",
"     </li>",
"     <li>",
"      Teolong (BR, PY);",
"     </li>",
"     <li>",
"      Teoplus (DO, GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Teosona (AR);",
"     </li>",
"     <li>",
"      Teotard (BG, EE, HR, RU);",
"     </li>",
"     <li>",
"      Theo PA (IN);",
"     </li>",
"     <li>",
"      Theo-2 (BE, LU);",
"     </li>",
"     <li>",
"      Theo-24 (IT);",
"     </li>",
"     <li>",
"      Theo-Bros (GR);",
"     </li>",
"     <li>",
"      Theo-Dur (AR, CZ, DK, FI, GR, IT, JP, LU, MY, NO, PK, SE, TR);",
"     </li>",
"     <li>",
"      Theoclear (KP);",
"     </li>",
"     <li>",
"      Theolair (CH, ES, IT, LU, NL);",
"     </li>",
"     <li>",
"      Theolair S (PE);",
"     </li>",
"     <li>",
"      Theolan (KP);",
"     </li>",
"     <li>",
"      Theolin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Theolin SR (SG);",
"     </li>",
"     <li>",
"      Theolong (JP);",
"     </li>",
"     <li>",
"      Theophtard (HU);",
"     </li>",
"     <li>",
"      Theophyllin-ratiopharm (LU);",
"     </li>",
"     <li>",
"      Theophylline Bruneau (LU);",
"     </li>",
"     <li>",
"      Theoplus Retard (AT, GR);",
"     </li>",
"     <li>",
"      Theospirex (HU);",
"     </li>",
"     <li>",
"      Theospirex Retard (AT);",
"     </li>",
"     <li>",
"      Theostat (LU);",
"     </li>",
"     <li>",
"      Theostat LP (FR);",
"     </li>",
"     <li>",
"      Theotard (IL);",
"     </li>",
"     <li>",
"      Uni-Dur (HR);",
"     </li>",
"     <li>",
"      Unicontin (PT);",
"     </li>",
"     <li>",
"      Unicontin-400 Continus (IN);",
"     </li>",
"     <li>",
"      Unifyl Retard (CH);",
"     </li>",
"     <li>",
"      Uniphyllin (TW);",
"     </li>",
"     <li>",
"      Uniphyllin Continus (BF, BJ, CI, ET, GB, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Xanthium (LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F226514\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Causes bronchodilatation, diuresis, CNS and cardiac stimulation, and gastric acid secretion by blocking phosphodiesterase which increases tissue concentrations of cyclic adenine monophosphate (cAMP) which in turn promotes catecholamine stimulation of lipolysis, glycogenolysis, and gluconeogenesis and induces release of epinephrine from adrenal medulla cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F226531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Dosage form dependent",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 0.45 L/kg (range: 0.3-0.7 L/kg) based on ideal body weight; distributes poorly into body fat; V",
"     <sub>",
"      d",
"     </sub>",
"     may increase in premature neonates, patients with hepatic cirrhosis, acidemia (uncorrected), the elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Children &gt;1 year and Adults: Hepatic; involves CYP1A2, 2E1 and 3A4; forms active metabolites (caffeine and 3-methylxanthine)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 40%, primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Highly variable and dependent upon age, liver function, cardiac function, lung disease, and smoking history",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature infants, postnatal age 3-15 days: 30 hours (range: 17-43 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Premature infants, postnatal age 25-57 days: 20 hours (range: 9.4-30.6 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 6-17 years: 3.7 hours (range: 1.5-5.9 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults 16-60 years with asthma, nonsmoking, otherwise healthy: 8.7 hours (range: 6.1-12.8 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Liquid: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: Within 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates: 50% as unchanged theophylline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;3 months and Adults: ~10% as unchanged theophylline",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;American Academy of Pediatrics Committee on Drugs. The Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30200/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 3, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo; Clinical Practice Guidelines, National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for Asthma Management and Prevention",
"      </i>",
"      , Global Initiative for Asthma (GINA) 2011. Available at file://www.ginasthma.org",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for the Diagnosis, Management and Prevention of COPD",
"      </i>",
"      , Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013. Available at file://www.goldcopd.com",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lougheed MD, Lemi&egrave;re C, Dell SD, et al, &ldquo;Canadian Thoracic Society Asthma Management Continuum - 2010 Consensus Summary for Children Six Years of Age and Over, and Adults,&rdquo;",
"      <i>",
"       Can Respir J",
"      </i>",
"      , 2010, 17(1):15-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30200/abstract-text/20186367/pubmed\" id=\"20186367\" target=\"_blank\">",
"        20186367",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute; National Asthma Education and Prevention Program Asthma and Pregnancy Working Group, &ldquo;NAEPP Expert Panel Report. Managing Asthma During Pregnancy: Recommendations for Pharmacologic Treatment - 2004 Update,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      ,  2005, 115(1):34-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/31/30200/abstract-text/15637545/pubmed\" id=\"15637545\" target=\"_blank\">",
"        15637545",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10281 Version 48.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.211.0.116-02955DDE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30200=[""].join("\n");
var outline_f29_31_30200=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226552\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226553\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226601\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226557\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226578\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226558\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226525\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226511\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226529\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226605\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226528\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226599\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226532\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226515\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226596\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226520\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226548\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226521\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226536\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226562\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226537\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226538\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226535\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6871829\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6871828\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226539\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226514\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226531\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10281\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10281|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/7/1141?source=related_link\">",
"      Theophylline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?23/49/24344?source=related_link\">",
"      Theophylline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30201="Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease";
var content_f29_31_30201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features, diagnosis, and natural history of lower extremity peripheral artery disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30201/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30201/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/31/30201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with compromised blood flow to the extremities as a consequence of peripheral artery disease (PAD) may present with pain of one or more muscle groups, atypical pain or no symptoms. Intermittent claudication (derived from the Latin word for limp) is defined as a reproducible discomfort of a defined group of muscles that is induced by exercise and relieved with rest. This disorder results from an imbalance between supply and demand of blood flow that fails to satisfy ongoing metabolic requirements.",
"   </p>",
"   <p>",
"    The etiology, risk factors, and clinical manifestations of claudication are reviewed here, with emphasis upon the presentation of arterial disease due to atherosclerosis (ie, PAD). The frequency of asymptomatic disease will also be discussed. The noninvasive evaluation and management of this disorder by medical therapy, percutaneous intervention, and surgery are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link\">",
"     \"Medical management of claudication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=see_link\">",
"     \"Indications for surgery in the patient with lower extremity claudication\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of patients with PAD have atherosclerotic disease of the lower extremity. Atherosclerotic PAD of the upper extremity is much less common and is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=see_link\">",
"     \"Overview of upper extremity peripheral artery disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although many diseases can cause intermittent claudication, the vast majority of patients with claudication suffer from PAD. The clinical history can help distinguish among some of the less common causes of this disorder (",
"    <a class=\"graphic graphic_table graphicRef75390 \" href=\"UTD.htm?38/20/39243\">",
"     table 1",
"    </a>",
"    ). As examples, a history of limb trauma, radiation exposure, vasculitis, or ergot use for migraines represents some important clues to the etiology of claudication.",
"   </p>",
"   <p>",
"    Popliteal entrapment syndrome can also present with intermittent claudication, and should be suspected in the young patient who presents with claudication but lacks atherosclerotic risk factors. Popliteal entrapment syndrome is due to anomalous musculoskeletal attachments, which cause compression of the popliteal artery with activity.",
"   </p>",
"   <p>",
"    In endurance athletes, especially cyclists, an even more unusual cause of claudication is due to repeated kinking of the external iliac artery, which can result in endofibrosis of the vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Non-arterial pathologic conditions should also be considered in the differential diagnosis of limb discomfort. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below.) These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep venous thrombosis",
"     </li>",
"     <li>",
"      Musculoskeletal disorders",
"     </li>",
"     <li>",
"      Peripheral neuropathy",
"     </li>",
"     <li>",
"      Spinal stenosis (pseudoclaudication)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of PAD increases progressively with age, beginning after age 40 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. As a result, PAD is growing as a clinical problem due to the increasingly aged population in the United States and other developed countries.",
"   </p>",
"   <p>",
"    The relationship between PAD prevalence and age was illustrated in an analysis of 2174 participants &ge;40 years of age in the 1999 to 2000 National Health and Nutrition Examination Survey (NHANES) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence of PAD, defined as an ankle-brachial index (ABI) &lt;0.90 in either leg, was 0.9 percent between the ages of 40 and 49, 2.5 percent between the ages of 50 and 59, 4.7 percent between the ages of 60 and 69, and 14.5 percent age 70 and older. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A higher prevalence was noted in the PARTNERS program of primary care practices across the United States, in which almost 7000 patients age &ge;70 years or 50 to 69 years with a history of cigarette smoking (more than 10 pack-years) or diabetes were evaluated by history and by ABI (with a value &le;0.90 considered diagnostic of PAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8\">",
"     8",
"    </a>",
"    ]. PAD was present in 29 percent overall: 13 percent had PAD alone (55 percent newly diagnosed) and 16 percent had PAD and cardiovascular disease (35 percent newly diagnosed). Cardiovascular disease (CVD) was defined as a history of atherosclerotic coronary, cerebral, or abdominal aortic aneurysmal disease. A classic history of claudication, as described below, was present in only 11 percent of patients with PAD.",
"   </p>",
"   <p>",
"    The 2007 TASC II consensus document on the management of PAD made the following estimates for the prevalence of PAD in Europe and North America [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      27 million affected individuals",
"     </li>",
"     <li>",
"      413,000 hospital discharges of patients with chronic PAD per year with 88,000 hospitalizations involving lower extremity arteriography and 28,000 discharges for embolectomy or thrombectomy of lower limb arteries.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors that favor the development of peripheral artery disease (ie, hyperlipidemia, smoking, hypertension, diabetes) are similar to those that promote the development of coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/7,8,10-14\">",
"     7,8,10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the Framingham Heart Study of 381 men and women who were followed for 38 years revealed that the odds ratio for developing intermittent claudication was 1.2 for each 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    elevation in the serum cholesterol concentration, 1.4 for each 10 cigarettes smoked per day, 1.5 for mild and 2.2 for moderate hypertension, and 2.6 for diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/11\">",
"     11",
"    </a>",
"    ]. Patients with diabetes have more advanced arterial disease and poorer outcomes than nondiabetic patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings were noted in NHANES analysis cited above of 2174 patients aged 40 and older [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/7\">",
"     7",
"    </a>",
"    ]. The risk of PAD was significantly increased in current smokers (odds ratio [OR] 4.46) and for patients with diabetes (OR 2.71), hypertension (OR 1.75), or hypercholesterolemia (OR 1.68). Other significant risk factors were black race (OR 2.83) and decreased renal function (OR 2.00).",
"   </p>",
"   <p>",
"    Patients with PAD are more likely to have increased levels of triglycerides",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholesterol, apolipoprotein B, and very low density lipoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Conversely, high density lipoprotein cholesterol and apolipoprotein A-I and A-II values, the \"protective\" lipoproteins, are reduced in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk of intermittent claudication may also be increased in patients with elevated plasma lipoprotein(a) and fibrinogen levels [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A diagnosis of metabolic syndrome (ie, obesity, hypercholesterolemia, hypertension, insulin resistance) is associated with increased risk of PAD. A prospective cohort study followed 27,111 women free of baseline cardiovascular disease over an average of 13.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/23\">",
"     23",
"    </a>",
"    ]. Compared with women without metabolic syndrome, women with metabolic syndrome had a 62 percent increased risk for future symptomatic PAD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=see_link&amp;anchor=H13#H13\">",
"     \"The metabolic syndrome (insulin resistance syndrome or syndrome X)\", section on 'Risk of CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not only are these atherosclerotic risk factors associated with an increased prevalence of PAD, they are also associated with earlier PAD onset. Patients who are 50 to 69 years with a history of cigarette smoking (more than 10 pack-years) or diabetes may have an incidence of asymptomatic PAD similar to patients &ge;70 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ethnic-related differences have been documented in prevalence rates of risk factors known to be associated with PAD. African and Hispanic Americans have higher rates of diabetes and hypertension, whereas white Americans are more likely to have hypercholesterolemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/24\">",
"     24",
"    </a>",
"    ]. In a population-based epidemiologic survey of 2343 randomly-selected participants in San Diego [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/25\">",
"     25",
"    </a>",
"    ], PAD was defined as an ankle-to-brachial index &le;0.90, an abnormal Doppler waveform, or prior revascularization for PAD. Blacks had a significantly higher prevalence of PAD than non-Hispanic whites (7.8 versus 4.9 percent, OR 2.30). Although blacks had significantly higher rates of diabetes and hypertension and a significant increase in body mass index, the increase in risk for PAD was similar after adjustment for these and other variables. Hispanics and Asians had somewhat lower rates of PAD than non-Hispanic whites, but the number of affected patients was small and the difference was not significant.",
"   </p>",
"   <p>",
"    Based, in part, upon the above observations, the 2005 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on PAD, which were produced in collaboration with major vascular medicine, vascular surgery, and interventional radiology societies, identified the following groups at risk for lower extremity PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age &ge;70 years.",
"     </li>",
"     <li>",
"      Age 50 to 69 years with a history of smoking or diabetes.",
"     </li>",
"     <li>",
"      Age 40 to 49 with diabetes and at least one other risk factor for atherosclerosis.",
"     </li>",
"     <li>",
"      Leg symptoms suggestive of claudication with exertion or ischemic pain at rest.",
"     </li>",
"     <li>",
"      Abnormal lower extremity pulse examination.",
"     </li>",
"     <li>",
"      Known atherosclerosis at other sites (eg, coronary, carotid, or renal artery disease).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PAD often present with symptoms of leg ischemia. However, many patients are asymptomatic, particularly those first detected by ABI screening, and, among symptomatic patients, atypical symptoms are more common than classic claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8,27,28\">",
"     8,27,28",
"    </a>",
"    ]. The 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on PAD suggested the following distribution of clinical presentation of PAD in patients &ge;50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic &ndash; 20 to 50 percent",
"     </li>",
"     <li>",
"      Atypical leg pain &ndash; 40 to 50 percent",
"     </li>",
"     <li>",
"      Classic claudication &ndash; 10 to 35 percent",
"     </li>",
"     <li>",
"      Critical limb ischemia &ndash; 1 to 2 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two classification systems have been used for chronic lower extremity PAD: the Fontaine system and the Rutherford system. Both are based upon the severity of symptoms and the presence of markers for severe chronic occlusive disease, such as ulceration and gangrene (",
"    <a class=\"graphic graphic_table graphicRef57359 \" href=\"UTD.htm?10/8/10380\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Symptomatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among symptomatic patients, the perception of claudication can vary from severe, debilitating discomfort at rest to a bothersome pain of seemingly little consequence. The severity of symptoms of claudication depends upon the degree of stenosis, the collateral circulation, and the vigor of exercise.",
"   </p>",
"   <p>",
"    Patients with claudication can present with buttock and hip, thigh, calf, or foot pain, either singly or in combination. The usual relationships between pain location and corresponding anatomic site of arterial occlusive disease can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Buttock and hip &ndash; aortoiliac disease",
"     </li>",
"     <li>",
"      Thigh &ndash; aortoiliac or common femoral artery",
"     </li>",
"     <li>",
"      Upper two-thirds of the calf &ndash; superficial femoral artery",
"     </li>",
"     <li>",
"      Lower one-third of the calf &ndash; popliteal artery",
"     </li>",
"     <li>",
"      Foot claudication &ndash; tibial or peroneal artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Physical examination in the patient with claudication can be normal, but commonly reveals diminished or absent pulses below the level of stenosis with occasional bruits over stenotic lesions and evidence of poor wound healing over the area of diminished perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Other physical findings may include a unilaterally cool extremity, a prolonged venous filling time, shiny atrophied skin, and nail changes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/29\">",
"     29",
"    </a>",
"    ]. The absence of hair is not a clinical predictor of the presence of PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical signs can also help determine the extent and distribution of vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/29\">",
"     29",
"    </a>",
"    ]. These include an abnormal femoral pulse, lower extremity bruits, and the Buerger test (foot pallor with elevation of the leg and, in the dependent position, a dusky red flush spreading proximally from the toes).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Buttock and hip claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with aortoiliac occlusive disease may complain of buttock, hip, and, in some cases, thigh claudication. The pain is often described as aching in nature and may be associated with weakness of the hip or thigh with walking. Bilateral aortoiliac disease that is severe enough to cause lower extremity symptoms almost always causes erectile dysfunction in men; another diagnosis should therefore be entertained if impotence is absent. Leriche syndrome is the triad of claudication, absent or diminished femoral pulses and erectile dysfunction.",
"   </p>",
"   <p>",
"    Physical examination reveals bilateral diminished or absent pulses at the level of the groin, with occasional bruits over the iliac and femoral arteries. Other findings include muscle atrophy and slow wound healing in the legs.",
"   </p>",
"   <p>",
"    Conditions that resemble Leriche's syndrome are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Osteoarthritis of the hip or knee joints &ndash; Osteoarthritis can be distinguished clinically from aortoiliac disease because osteoarthritic pain may not disappear promptly after exercise, may be associated with weather changes, and may vary in intensity from day to day (usually worse in the morning or upon wakening).",
"     </li>",
"     <li>",
"      Neurogenic claudication &ndash; Neurogenic claudication, also called pseudoclaudication, describes a pain syndrome due to lumbar neurospinal canal compression, which is usually due to osteophytic narrowing of the neurospinal canal. The clinical presentation often helps to distinguish vasculogenic (ie, true) claudication from pseudoclaudication. Unlike true claudication, which occurs with walking and is relieved by stopping, pseudoclaudication causes pain with erect posture (lumbar lordosis) and is relieved by sitting or lying down. Patients with pseudoclaudication may also find symptomatic relief by leaning forward and straightening the spine (usually done with pushing a shopping cart or leaning against a wall). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=see_link\">",
"       \"Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Thigh claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atherosclerotic occlusion of the common femoral artery may induce claudication in the thigh, calf, or both. Patients with occlusive disease of the superficial femoral or popliteal arteries have normal groin pulses but decreased pulses distally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Calf claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calf claudication is the most common complaint. It is usually described as escalating pain that is consistently reproduced with exercise and relieved with rest. Pain in the upper two-thirds of the calf is usually due to superficial femoral artery stenosis, whereas pain in the lower third of the calf is due to popliteal disease. This type of pain in the calf can be confused with two other conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nocturnal leg cramps &ndash; Nocturnal leg cramps occur among older and infirmed patients and are not associated with exercise. This complaint is thought to be neuromuscular rather than vascular in origin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=see_link\">",
"       \"Nocturnal leg cramps\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Calf pressure and tightness &ndash; This symptom is primarily seen in athletes, and is usually associated with chronic exercise. It is thought to be due to increased compartment pressure and may persist even after rest.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Foot claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Claudication of the foot is usually accompanied by occlusive disease of the tibial and peroneal vessels. Isolated foot claudication is rarely seen with atherosclerotic occlusive disease, but is commonly seen with thromboangiitis obliterans (Buerger's disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8170?source=see_link\">",
"     \"Thromboangiitis obliterans (Buerger's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Ischemic rest pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;A severe decrease in limb perfusion can result in ischemic rest pain. Such discomfort typically occurs at night and involves the digits and forefoot. The pain may be more localized in patients who develop an ischemic ulcer or gangrenous toe.",
"   </p>",
"   <p>",
"    Affected patients frequently find that the pain is relieved by hanging their feet over the edge of the bed or, paradoxically, by walking around the room because of the gravitational effect of dependence on limb blood pressure. Chronic tissue ischemia may also result in ischemic neuropathic pain that is frequently described as throbbing or burning with a superimposed severe shooting pain up the limb.",
"   </p>",
"   <p>",
"    The clinical manifestations of critical limb ischemia (also called limb-threatening ischemia) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=see_link\">",
"     \"Clinical manifestations and evaluation of chronic critical limb ischemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Atypical symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with PAD have atypical symptoms as a result of comorbidities, physical inactivity, and alterations in pain perception. This issue was addressed in a study of 460 men and women with known PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/27\">",
"     27",
"    </a>",
"    ]. Symptoms were classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classic claudication &ndash; Exertional calf pain that does not begin at rest, causes the patient to stop walking, and resolves within 10 minutes of rest; 150 patients (33 percent)",
"     </li>",
"     <li>",
"      Atypical exertional leg pain type I &ndash; Pain similar to that of classic claudication, but does not cause the patient to stop walking; 41 patients (9 percent)",
"     </li>",
"     <li>",
"      Atypical exertional leg pain type II &ndash; Pain similar to that of classic claudication, but does not involve the calves or does not resolve within 10 minutes of rest; 90 patients (20 percent)",
"     </li>",
"     <li>",
"      Leg pain on both exertion and rest &ndash; 88 patients (19 percent)",
"     </li>",
"     <li>",
"      No exertional leg pain, physically active (walked more than six blocks in previous week) &ndash; 63 patients (14 percent)",
"     </li>",
"     <li>",
"      No exertional leg pain, physically inactive &ndash; 28 patients (6 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Compared with patients with classic claudication, those with leg pain on both exertion and rest were more likely to have diabetes, neuropathy, or spinal stenosis in addition to PAD. Functional capacity varied among groups, being best among those with type I atypical exertional leg pain and worst among those with pain on both exertion and rest.",
"   </p>",
"   <p>",
"    A much lower rate of classic claudication was noted in the report from the PARTNERS program cited above, in which 6417 patients were at risk for PAD (either age &ge;70 or age 50 to 69 with a history of diabetes or more than 10 pack-years of cigarette smoking) in a primary care setting [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8\">",
"     8",
"    </a>",
"    ]. PAD, identified by the ABI or by history, was present in 29 percent:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the patients with a new diagnosis of PAD, approximately 47 percent had no history of leg symptoms, 47 percent had atypical leg symptoms, and only 6 percent had classic claudication.",
"     </li>",
"     <li>",
"      Among the patients with known prior PAD, approximately 25 percent had no leg symptoms, 61 percent had atypical leg symptoms, and 14 percent had classic claudication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Asymptomatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with PAD have unrecognized disease as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PARTNERS program cited above evaluated 6417 patients at risk for PAD (either age &ge;70 or age 50 to 69 with a history of diabetes or more than 10 pack-years of cigarette smoking) in a primary care setting [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8\">",
"       8",
"      </a>",
"      ]. PAD, identified by the ABI or by history, was present in 29 percent. Among the patients with a new diagnosis of PAD, approximately 45 percent had no history of leg symptoms and only 5.5 percent had classic claudication.",
"     </li>",
"     <li>",
"      Another study included 239 men and women ages 55 and older with no history of PAD who were recruited from a general internal medicine practice [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/32\">",
"       32",
"      </a>",
"      ]. The ABI was abnormal (&lt;0.90) in 14 percent. Most of these patients did not report exertional leg symptoms. However, they were not able to walk as far in six minutes as a group of patients without PAD (1362 versus 1539 feet).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For asymptomatic patients, a systematic review of studies comparing clinical signs of PAD to ABI, duplex ultrasound, or angiography found the presence of any bruit, pulse abnormality, or cool skin increases the likelihood of PAD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/30\">",
"     30",
"    </a>",
"    ]. The physical examination is performed only after the patient has rested for at least 15 minutes, and has warmed up if coming indoors from cold weather.",
"   </p>",
"   <p>",
"    Detection of asymptomatic PAD has value because it identifies patients at increased risk of atherosclerosis at other sites. As an example: as many as 50 percent of patients with PAD have at least a 50 percent stenosis in one renal artery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, patients with asymptomatic PAD, most often detected by ABI, should be treated to reduce their risk (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , lipid lowering, blood pressure control). In addition to protecting against coronary disease and stroke, lipid lowering may also slow progression of the PAD (as measured by angiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=see_link&amp;anchor=H2#H2\">",
"     \"Medical management of claudication\", section on 'Risk factor modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Activity level",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted in some of the studies described above, functional capacity is diminished in some patients with PAD, even in the absence of claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/32,35\">",
"     32,35",
"    </a>",
"    ]. In addition, a gradual decline in activity level may mask the symptoms and lead to an underestimation of disease severity.",
"   </p>",
"   <p>",
"    This issue was addressed in a study of 417 patients with PAD and 259 without disease who underwent measurement of ABI and assessment of functional capacity at baseline and one and two years later [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with an ABI &lt;0.50 had a significantly greater annual decline in six-minute walk distance than those with an ABI of 0.50 to &lt;0.90 or those with an ABI of 0.90 to 1.50 (73 versus 59 and 13 feet, respectively). In addition, patients with PAD who reported no exertional pain had a greater annual decline in six-minute walk distance than those with intermittent claudication (77 versus 36 feet).",
"   </p>",
"   <p>",
"    These findings suggest that activity level is an important factor in the evaluation of patients with PAD. Patients with evidence of PAD who report no or few symptoms should be asked about functional capacity and decline in activity over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Correlation of ABI with symptoms and site of PAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a general, but not absolute, correlation between symptoms and the site and severity of PAD, with severity being estimated from the ankle-brachial index (ABI, abnormal &lt;0.90). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This was illustrated in a study using a claudication questionnaire for exertional leg pain in 3658 subjects, 24 percent of whom had PAD (defined as an ABI &lt;0.90) in one or both legs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/36\">",
"     36",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At ABIs of 1.00 to 1.09 (normal), 0.80 to 0.89 (just abnormal), and 0.40 to 0.49 (markedly reduced), the proportion of legs with any leg pain increased progressively from 18 percent to 61 percent to 83 percent. Pain was also more common in legs with ABIs &ge;1.40, a presumed marker of vascular stiffness",
"     </li>",
"     <li>",
"      At ABIs of 1.00 to 1.09 (normal), 0.80 to 0.89 (just abnormal), and 0.40 to 0.49 (markedly reduced), the proportion of legs with classic claudication increased progressively from 2 percent to 22 percent to 46 percent. In contrast, atypical pain and noncalf pain did not show much correlation with the ABI. Pain occurring at rest was the most common pain symptom in patients without PAD.",
"     </li>",
"     <li>",
"      Discordance was noted in some patients between the site of PAD and the site of pain. Patients with unilateral PAD were more likely to report bilateral than unilateral pain (42 versus 29 percent). Furthermore, among 80 patients with unilateral PAD and unilateral pain, the pain was in the other leg in 11 (14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Not surprisingly, since PAD is a manifestation of systemic atherosclerosis, a low ABI is also predictive of an increased risk of all-cause and cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/37,38\">",
"     37,38",
"    </a>",
"    ] and of the development of coronary artery calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=see_link\">",
"     \"Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, there is a high prevalence of lower extremity PAD in patients over age 70 and in patients between the ages of 50 and 69 with atherosclerotic risk factors, particularly smoking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Based upon these observations, the 2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on PAD and the 2007 TASC II consensus document on the management of PAD recommended that the standard review of symptoms should include questions related to a history of walking impairment, symptoms of claudication, ischemic rest pain, or nonhealing wounds in patients &ge;70 years of age, those &ge;50 years of age with a history of smoking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diabetes, or, in TASC II, those with a Framingham risk score of 10 to 20 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/9,26\">",
"     9,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=see_link&amp;anchor=H8#H8\">",
"     \"Estimation of cardiovascular risk in an individual patient without known cardiovascular disease\", section on 'Multivariate risk models'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Measurement of the resting ankle-brachial systolic pressure index (ABI) should be performed in patients with one or more of the above findings on the review of symptoms. An ABI of &le;0.90 has a high degree of sensitivity and specificity for the diagnosis, using arteriography as the gold standard [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"     \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classic claudication is characterized by leg pain that is consistently reproduced with exercise and relieved with rest. However, many patients have atypical symptoms that may be confused with a number of other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8,9,27\">",
"     8,9,27",
"    </a>",
"    ]. The etiology of leg pain can be divided into categories that include vascular, neurogenic, and musculoskeletal causes. Vascular pain includes classic claudication, \"atypical\" claudication, and rest pain.",
"   </p>",
"   <p>",
"    Any process that results in arterial stenosis or occlusion can cause symptoms of claudication, ischemic pain, or tissue loss. These include arterial thrombosis due to aneurysm, arterial injury, arterial dissection, or thromboembolism. Other causes are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef75390 \" href=\"UTD.htm?38/20/39243\">",
"     table 1",
"    </a>",
"    ). The popliteal artery is the most common site of a peripheral artery aneurysm with symptoms of lower extremity ischemia due to embolism of mural thrombus or aneurysm thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/40\">",
"     40",
"    </a>",
"    ]. Although less common, aneurysms at other sites can also be the source of embolic debris leading to arterial obstruction. The presence of a peripheral aneurysm should prompt evaluation for other aneurysms [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/41\">",
"     41",
"    </a>",
"    ].The clinical evaluation of aneurysmal disease is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=see_link\">",
"     \"Popliteal artery aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29304?source=see_link\">",
"     \"Iliac artery aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=see_link\">",
"     \"Clinical features and diagnosis of abdominal aortic aneurysm\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other vascular etiologies that can lead to lower extremity ischemia include limb trauma, radiation exposure, vasculitis, or ergot use for migraines. Popliteal entrapment syndrome can also present with intermittent claudication, and should be suspected in the young patient who presents with claudication but lacks atherosclerotic risk factors. Popliteal entrapment syndrome is due to anomalous musculoskeletal attachments or an abnormal course of the popliteal artery, which cause compression of the popliteal artery with activity.",
"   </p>",
"   <p>",
"    In endurance athletes, especially cyclists, an even more unusual cause of claudication is due to repeated trauma (stretching or kinking) of the external iliac artery, which can result in endofibrosis of the vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/1\">",
"     1",
"    </a>",
"    ]. Nonarterial pathologic conditions should also be considered in the differential diagnosis of limb pain. These include neurological disorders, musculoskeletal disorders and venous disorders.",
"   </p>",
"   <p>",
"    Neurological pain (&ldquo;spinal claudication&rdquo;) is predominantly due to neurospinal (eg, disc disease, spinal stenosis, tumor) or neuropathic causes (eg, diabetes, alcohol abuse). Musculoskeletal pain derives from the bones, joints, ligaments, tendons, and fascial elements of the lower extremity. Chronic venous disease can cause &ldquo;venous claudication&rdquo; but is usually easily distinguished from arterial claudication by a variable degree of limb swelling and increased discomfort with limb dependency. The major clinical features that distinguish these disorders from arterial claudication are given in the table (",
"    <a class=\"graphic graphic_table graphicRef50130 \" href=\"UTD.htm?43/8/44172\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Atypical symptoms'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors that predict progression of PAD were evaluated in a longitudinal study of 403 patients at baseline and at a mean follow-up of 4.6 years using a standard questionnaire, clinical examination, and noninvasive testing assessing the ankle-to-brachial index (ABI) and the toe-brachial index [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/42\">",
"     42",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with the largest fall in ABI, current cigarette smoking, the ratio of total to HDL cholesterol, hs-CRP, and Lp(a) were statistically important predictors.",
"     </li>",
"     <li>",
"      Among patients with the largest fall in toe-brachial index, diabetes was the only significant predictor of progression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Claudication",
"    </span>",
"    &nbsp;&mdash;&nbsp;2005",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines on PAD estimated the following rates of limb and cardiovascular outcomes at five years in patients with claudication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For limb morbidity &ndash; Stable claudication in 70 to 80 percent, worsening claudication in 10 to 20 percent, and critical limb ischemia in 1 to 2 percent",
"     </li>",
"     <li>",
"      For cardiovascular morbidity and mortality &ndash; Nonfatal myocardial infarction or stroke in 20 percent, and death in 15 to 30 percent (three-quarters due to cardiovascular causes); an association between cardiovascular disease and PAD has been noted in multiple studies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/37,38,43\">",
"       37,38,43",
"      </a>",
"      ]. The importance of PAD as a marker for coexistent coronary artery disease cannot be overstated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Critical limb ischemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 1 to 2 percent of patients with critical limb ischemia, the guidelines estimated the following outcomes at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alive with two limbs &ndash; 50 percent",
"     </li>",
"     <li>",
"      Amputation &ndash; 25 percent",
"     </li>",
"     <li>",
"      Cardiovascular mortality &ndash; 25 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These general estimates do not apply equally to all patients. The risk factors for progressive PAD are described above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/42\">",
"     42",
"    </a>",
"    ]. The prognosis for both limb loss and survival is significantly worse in diabetic patients and those who continue to smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30201/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=see_link\">",
"       \"Patient information: Peripheral artery disease and claudication (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519581089\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of peripheral artery disease (PAD) increases progressively with age, beginning after age 40. As a result, PAD is growing as a clinical problem due to the aging population in the United States and other developed countries. As such, a standard review during the examination of older patients should always include questions related to a history of walking impairment, extremity pain that might be due to ischemia and the presence of nonhealing wounds. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The etiology of extremity pain can be divided into categories that include vascular, neurogenic, and musculoskeletal causes. Any process that leads to arterial stenosis or occlusion can cause symptoms of lower extremity ischemia (",
"      <a class=\"graphic graphic_table graphicRef75390 \" href=\"UTD.htm?38/20/39243\">",
"       table 1",
"      </a>",
"      ). Nonarterial pathologic conditions should also be considered, including neurological disorders, musculoskeletal disorders, and acute and chronic venous disease such as deep vein thrombosis or postthrombotic syndrome. The presenting clinical features should help distinguish atypical symptoms of PAD from other causes of extremity pain (",
"      <a class=\"graphic graphic_table graphicRef50130 \" href=\"UTD.htm?43/8/44172\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with compromised blood flow to the extremities as a consequence of arterial stenosis due to PAD may present with pain of one or more muscle groups, atypical pain, or no symptoms. Intermittent claudication (derived from the Latin word for limp) is defined as a reproducible discomfort of a defined group of muscles that is induced by exercise and relieved with rest. This disorder results from an imbalance between supply and demand of blood flow that fails to satisfy ongoing metabolic requirements. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for peripheral artery disease are similar to those that promote the development of coronary atherosclerosis (ie, hyperlipidemia, smoking, hypertension, diabetes). The 2005 American College of",
"      <span class=\"nowrap\">",
"       Cardiology/American",
"      </span>",
"      Heart Association",
"      <span class=\"nowrap\">",
"       (ACC/AHA)",
"      </span>",
"      guidelines on PAD identified the following groups at risk for lower extremity PAD:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      age &ge;70 years",
"     </li>",
"     <li>",
"      age 50 to 69 years with a history of smoking or diabetes",
"     </li>",
"     <li>",
"      age 40 to 49 with diabetes and at least one other risk factor for atherosclerosis",
"     </li>",
"     <li>",
"      leg symptoms suggestive of claudication with exertion or ischemic pain at rest",
"     </li>",
"     <li>",
"      abnormal lower extremity pulse examination",
"     </li>",
"     <li>",
"      known atherosclerosis at other sites (eg, coronary, carotid, renal artery disease)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ethnic-related differences have been documented with African Americans having a higher prevalence of PAD than non-Hispanic whites, and Hispanics and Asians having a somewhat lower rate of PAD than non-Hispanic whites. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"      <br/>",
"     </li>",
"     <li>",
"      Patients with risk factors for PAD who report no or few symptoms should be asked about functional capacity and decline in activity over time. Not surprisingly, since PAD is a manifestation of systemic atherosclerosis, a diagnosis of PAD predicts an increased risk of all-cause and cardiovascular mortality. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Asymptomatic disease'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=see_link\">",
"       \"Screening for lower extremity peripheral artery disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"       \"Secondary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Classic claudication is characterized by leg pain that is consistently reproduced with exercise and relieved with rest. The degree of symptoms of claudication depends upon the severity of stenosis, the collateral circulation, and the vigor of exercise. Patients with claudication can present with buttock, hip, thigh, calf, or foot pain, alone or in combination. The usual relationships between pain location and corresponding anatomic site of arterial occlusive disease can be summarized as follows: (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Symptomatic disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Buttock and hip: Aortoiliac disease",
"     </li>",
"     <li>",
"      Thigh: Aortoiliac or common femoral artery",
"     </li>",
"     <li>",
"      Upper two-thirds of the calf: Superficial femoral artery",
"     </li>",
"     <li>",
"      Lower one-third of the calf: Popliteal artery",
"     </li>",
"     <li>",
"      Foot claudication: Tibial or peroneal artery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe decreases in limb perfusion can result in ischemic rest pain which involves the digits and forefoot and typically occurs at night. The pain may be more localized in patients who develop an ischemic ulcer or gangrenous toe. The pain may be relieved by dependent positioning of the foot. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Ischemic rest pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with PAD have atypical symptoms as a result of comorbidities, physical inactivity, and alterations in pain perception. Compared with patients with classic claudication, those with leg pain on exertion and at rest are more likely to have diabetes, neuropathy, or spinal stenosis in addition to PAD. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Atypical symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To confirm the diagnosis of arterial stenosis or occlusion, which is most commonly due to PAD, the resting ankle-brachial systolic pressure index (ABI) should be performed in patients with lower extremity symptoms and in those patients with risk factors for PAD. An ABI of &le;0.90 has a high degree of sensitivity and specificity for a diagnosis of PAD. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=see_link&amp;anchor=H58544655#H58544655\">",
"       \"Noninvasive diagnosis of arterial disease\", section on 'Ankle-brachial index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The natural history of peripheral artery disease in patients who present initially with mild to moderate claudication is relatively benign with 70 to 80 percent of patients having stable claudication, 10 to 20 percent developing worsened claudication, and only about 1 to 2 percent progressing to critical limb ischemia. The prognosis for limb loss or survival is significantly worse in diabetic patients and for those who continue to smoke. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/1\">",
"      Schep G, Bender MH, van de Tempel G, et al. Detection and treatment of claudication due to functional iliac obstruction in top endurance athletes: a prospective study. Lancet 2002; 359:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/2\">",
"      Reeder BA, Liu L, Horlick L. Sociodemographic variation in the prevalence of cardiovascular disease. Can J Cardiol 1996; 12:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/3\">",
"      McDaniel MD, Cronenwett JL. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg 1989; 3:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/4\">",
"      Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985; 71:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/5\">",
"      Murabito JM, Evans JC, Nieto K, et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J 2002; 143:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/6\">",
"      Pasternak RC, Criqui MH, Benjamin EJ, et al. Atherosclerotic Vascular Disease Conference: Writing Group I: epidemiology. Circulation 2004; 109:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/7\">",
"      Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/8\">",
"      Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/9\">",
"      Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/10\">",
"      Smith SC Jr, Milani RV, Arnett DK, et al. Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors. Circulation 2004; 109:2613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/11\">",
"      Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation 1997; 96:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/12\">",
"      Zelis R, Mason DT, Braunwald E, Levy RI. Effects of hyperlipoproteinemias and their treatment on the peripheral circulation. J Clin Invest 1970; 49:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/13\">",
"      Couch NP. On the arterial consequences of smoking. J Vasc Surg 1986; 3:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/14\">",
"      Al-Delaimy WK, Merchant AT, Rimm EB, et al. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med 2004; 116:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/15\">",
"      Jude EB, Oyibo SO, Chalmers N, Boulton AJ. Peripheral arterial disease in diabetic and nondiabetic patients: a comparison of severity and outcome. Diabetes Care 2001; 24:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/16\">",
"      Vitale E, Zuliani G, Baroni L, et al. Lipoprotein abnormalities in patients with extra-coronary arteriosclerosis. Atherosclerosis 1990; 81:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/17\">",
"      Greenhalgh RM, Rosengarten DS, Mervart I, et al. Serum lipids and lipoproteins in peripheral vascular disease. Lancet 1971; 2:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/18\">",
"      Vogelberg KH, Berchtold P, Berger H, et al. Primary hyperlipoproteinemias as risk factors in peripheral artery disease documented by arteriography. Atherosclerosis 1975; 22:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/19\">",
"      Bradby GV, Valente AJ, Walton KW. Serum high-density lipoproteins in peripheral vascular disease. Lancet 1978; 2:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/20\">",
"      Cantin B, Moorjani S, Dagenais GR, Lupien PJ. Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Qu&eacute;bec Cardiovascular Study). Am J Cardiol 1995; 75:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/21\">",
"      Banerjee AK, Pearson J, Gilliland EL, et al. A six year prospective study of fibrinogen and other risk factors associated with mortality in stable claudicants. Thromb Haemost 1992; 68:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/22\">",
"      Lowe GD, Fowkes FG, Dawes J, et al. Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 1993; 87:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/23\">",
"      Conen D, Rexrode KM, Creager MA, et al. Metabolic syndrome, inflammation, and risk of symptomatic peripheral artery disease in women: a prospective study. Circulation 2009; 120:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/24\">",
"      Meadows TA, Bhatt DL, Hirsch AT, et al. Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry. Am Heart J 2009; 158:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/25\">",
"      Criqui MH, Vargas V, Denenberg JO, et al. Ethnicity and peripheral arterial disease: the San Diego Population Study. Circulation 2005; 112:2703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/26\">",
"      Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/27\">",
"      McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA 2001; 286:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/28\">",
"      European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/29\">",
"      McGee SR, Boyko EJ. Physical examination and chronic lower-extremity ischemia: a critical review. Arch Intern Med 1998; 158:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/30\">",
"      Khan NA, Rahim SA, Anand SS, et al. Does the clinical examination predict lower extremity peripheral arterial disease? JAMA 2006; 295:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/31\">",
"      Brueseke TJ, Macrino S, Miller JJ. Lack of lower extremity hair not a predictor for peripheral arterial disease. Arch Dermatol 2009; 145:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/32\">",
"      McDermott MM, Kerwin DR, Liu K, et al. Prevalence and significance of unrecognized lower extremity peripheral arterial disease in general medicine practice*. J Gen Intern Med 2001; 16:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/33\">",
"      Rimmer JM, Gennari FJ. Atherosclerotic renovascular disease and progressive renal failure. Ann Intern Med 1993; 118:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/34\">",
"      Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis. Cochrane Database Syst Rev 2000; :CD000123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/35\">",
"      McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. JAMA 2004; 292:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/36\">",
"      Wang JC, Criqui MH, Denenberg JO, et al. Exertional leg pain in patients with and without peripheral arterial disease. Circulation 2005; 112:3501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/37\">",
"      Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. BMJ 1996; 313:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/38\">",
"      O'Hare AM, Katz R, Shlipak MG, et al. Mortality and cardiovascular risk across the ankle-arm index spectrum: results from the Cardiovascular Health Study. Circulation 2006; 113:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/39\">",
"      Allison MA, Laughlin GA, Barrett-Connor E, Langer R. Association between the ankle-brachial index and future coronary calcium (the Rancho Bernardo study). Am J Cardiol 2006; 97:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/40\">",
"      Szilagyi DE, Schwartz RL, Reddy DJ. Popliteal arterial aneurysms. Their natural history and management. Arch Surg 1981; 116:724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/41\">",
"      Varga ZA, Locke-Edmunds JC, Baird RN. A multicenter study of popliteal aneurysms. Joint Vascular Research Group. J Vasc Surg 1994; 20:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/42\">",
"      Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006; 113:2623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/43\">",
"      Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30201/abstract/44\">",
"      Ouriel K. Peripheral arterial disease. Lancet 2001; 358:1257.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8208 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-7BCA055868-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30201=[""].join("\n");
var outline_f29_31_30201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H519581089\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Symptomatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Buttock and hip claudication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Thigh claudication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Calf claudication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Foot claudication",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Ischemic rest pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Atypical symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Asymptomatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Activity level",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Correlation of ABI with symptoms and site of PAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Claudication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519581089\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8208\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8208|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/20/39243\" title=\"table 1\">",
"      Etiology of lower extremity ischemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/8/10380\" title=\"table 2\">",
"      Fontaine stages and Rutherford categories PAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/8/44172\" title=\"table 3\">",
"      Differential diagnosis of claudication",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32010?source=related_link\">",
"      Clinical features and diagnosis of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14486?source=related_link\">",
"      Clinical manifestations and evaluation of chronic critical limb ischemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30410?source=related_link\">",
"      Diagnostic and prognostic implications of coronary artery calcification detected by computed tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/8/39048?source=related_link\">",
"      Estimation of cardiovascular risk in an individual patient without known cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29304?source=related_link\">",
"      Iliac artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44376?source=related_link\">",
"      Indications for surgery in the patient with lower extremity claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1480?source=related_link\">",
"      Lumbar spinal stenosis: Pathophysiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4711?source=related_link\">",
"      Nocturnal leg cramps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12245?source=related_link\">",
"      Overview of upper extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?14/35/14900?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/49/34578?source=related_link\">",
"      Patient information: Peripheral artery disease and claudication (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/63/3065?source=related_link\">",
"      Popliteal artery aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/40/24200?source=related_link\">",
"      Screening for lower extremity peripheral artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/11/32954?source=related_link\">",
"      The metabolic syndrome (insulin resistance syndrome or syndrome X)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8170?source=related_link\">",
"      Thromboangiitis obliterans (Buerger's disease)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30202="HIV infection and malignancy: Management considerations";
var content_f29_31_30202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV infection and malignancy: Management considerations",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/31/30202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30202/contributors\">",
"     Liron Pantanowitz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30202/contributors\">",
"     John F Deeken, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/31/30202/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30202/contributors\">",
"     Bruce J Dezube, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/31/30202/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/31/30202/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/31/30202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1560506014\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected individuals have an increased propensity to develop malignancy. The occurrence of an extremely high number of cases of Kaposi sarcoma (KS) was noted early in the AIDS epidemic and many of thee had an unusually aggressive clinical course. KS was therefore included as an AIDS-defining illness in early case definitions from the Centers for Disease Control and Prevention (CDC). Non-Hodgkin lymphoma (NHL) and invasive cervical carcinoma were subsequently added as AIDS-defining conditions.",
"   </p>",
"   <p>",
"    The spectrum of neoplasia in HIV infected patients has changed in areas where the use of potent antiretroviral therapy (ART) is widespread. The incidence of KS and NHL has decreased markedly, but there has been a relative increase in tumor types that collectively are referred to as non-AIDS-defining cancers (NADCs) compared with the general population. NADCs now are a major factor contributing to mortality in HIV-infected people.",
"   </p>",
"   <p>",
"    This topic will review general management considerations for patients with HIV and a malignancy, as well as a discussion of specific malignancies. The epidemiology and pathogenesis of malignancy in people infected with HIV are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link&amp;anchor=H1#H1\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506021\">",
"    <span class=\"h1\">",
"     CLINICAL IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignancies in patients infected with HIV are often characterized by earlier age at onset, atypical pathology (higher tumor grade), more aggressive clinical behavior,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more advanced stage at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These features may have implications for screening and treatment, and may contribute to a poorer outcome, with rapid progression, a high rate of relapse, and a worse response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506118\">",
"    <span class=\"h2\">",
"     Screening and prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased incidence of selected cancers in HIV-infected patients, combined with the younger age of onset and the altered biology, raise the question of whether more aggressive screening is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Most cancer screening guidelines do not make separate recommendations for individuals infected with HIV, with the exception of the European AIDS Clinical Society [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, routine screening for cancer is less frequent in HIV infected people than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinicians caring for HIV-infected individuals should adhere to age-appropriate screening recommendations for the common malignancies and should actively encourage compliance with those guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to screening, clinicians caring for HIV-infected individuals should make every effort to help patients minimize risk factors for cancer. Potential opportunities include smoking cessation programs, the use of human papillomavirus (HPV) and hepatitis B virus (HBV) vaccines, and the prevention or treatment of HBV or hepatitis C virus (HCV) infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=see_link\">",
"     \"Overview of smoking cessation management in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506125\">",
"    <span class=\"h2\">",
"     Principles of treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cancer in HIV-infected individuals follows the same general principles as for those not infected with HIV. The diagnosis of cancer should be confirmed pathologically. For patients with early stage disease, initial management is with curative intent, as is the case for non-HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Systemic therapy may be required for metastatic disease or as adjuvant therapy. The use of cytotoxic chemotherapy with antiretroviral therapy may result in additive cytotoxicity or other drug-drug interactions and may further enhance immunosuppression. The combination of chemotherapy and ART requires a careful consideration of such potential interactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42294?source=see_link\">",
"     \"Systemic therapy for malignancy in patients on anti retroviral medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other factors that can complicate the management of malignancy in an HIV-infected individual include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV-infected patients frequently often have significant comorbidities that result in a poor performance status and affect the response to treatment.",
"     </li>",
"     <li>",
"      The presence of reactive lymphadenopathy or other imaging abnormalities not related to the malignancy may complicate accurate tumor staging.",
"     </li>",
"     <li>",
"      HIV-infected individuals may be poor surgical candidates, because of an increased risk of developing postoperative infections particularly in those with predominantly late stage AIDS. Data from patients with early stage HIV disease found surgical risks were similar to those without HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506132\">",
"    <span class=\"h1\">",
"     AIDS-DEFINING MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaposi sarcoma (KS), selected types of NHL, and invasive cervical cancer are included in the criteria that define AIDS in people infected with HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506256\">",
"    <span class=\"h2\">",
"     Kaposi sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;KS is a low-grade soft tissue sarcoma of vascular origin that is associated with infection with human herpesvirus (HHV)-8 (also known as the KS-associated herpesvirus). Infection with HHV-8 precedes and is predictive of the development of KS. In a study of 800 men, 400 of whom were HIV-positive, the 10-year probability of developing KS was approximately 50 percent in those who were seropositive for both HIV and HHV-8 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    KS is primarily a disease of men; early in the HIV epidemic, KS was noted in 20 to 30 percent of HIV-infected men who have sex with men. With the widespread use of ART, the incidence decreased dramatically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link&amp;anchor=H1560489307#H1560489307\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AIDS-related KS has a variable clinical course, ranging from an asymptomatic incidental finding to explosive growth resulting in significant morbidity and mortality. Skin involvement is characteristic (",
"    <a class=\"graphic graphic_picture graphicRef60346 graphicRef69357 graphicRef79726 graphicRef74359 graphicRef78116 graphicRef79283 graphicRef70919 graphicRef52327 graphicRef65310 graphicRef60162 \" href=\"UTD.htm?0/4/67\">",
"     picture 1A-J",
"    </a>",
"    ) but extracutaneous spread is common, particularly to the oral cavity (",
"    <a class=\"graphic graphic_picture graphicRef61561 graphicRef50835 \" href=\"UTD.htm?31/62/32744\">",
"     picture 2A-B",
"    </a>",
"    ), lungs and digestive tract (",
"    <a class=\"graphic graphic_picture graphicRef59519 \" href=\"UTD.htm?28/31/29169\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=see_link&amp;anchor=H432027014#H432027014\">",
"     \"AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis\", section on 'Cutaneous KS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The major goals of treatment for AIDS-related KS are symptom palliation, prevention of disease progression, and shrinkage of tumor to alleviate edema, organ compromise, and psychological stress. Although there are no randomized trials evaluating the effect of ART, observational studies provide strong evidence that the natural history of KS has changed since its introduction; immune reconstitution due to control of the HIV infection is the most likely explanation for this altered prognosis. ART is recommended for virtually all patients with AIDS-related KS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=see_link\">",
"     \"Pulmonary involvement in AIDS-related Kaposi sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for treatment beyond potent ART and the choice among the various options depend upon the extent of disease, the rapidity of tumor growth, the HIV-1 viral load, the CD4 cell count, and the patient's overall medical condition. Locally directed therapy is often used to palliate symptoms caused by a specific tumor or to treat cosmetic disfigurement. Systemic therapy is used for more extensive disease but injury to an immune system that is already severely compromised should be avoided whenever possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=see_link\">",
"     \"AIDS-related Kaposi sarcoma: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506263\">",
"    <span class=\"h2\">",
"     Non-Hodgkin lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;NHLs that have been designated as AIDS defining include diffuse large B cell lymphoma, Burkitt&rsquo;s lymphoma, immunoblastic lymphoma, plasmablastic lymphoma, primary effusion lymphoma, and primary lymphoma of the brain. The incidence of NHL in HIV positive patients has fallen markedly since the introduction of ART. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link&amp;anchor=H1560489307#H1560489307\">",
"     \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NHLs in HIV-infected patients frequently arise in extranodal sites, such as the stomach or esophagus, and may constitute the majority of malignancies seen in those sites. (See",
"    <a class=\"local\" href=\"#H1560506438\">",
"     'Stomach and esophageal malignancies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The clinical manifestations and management of AIDS-defining NHL, as well as non-AIDS-defining NHL with an increased incidence in HIV infected individuals, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506277\">",
"    <span class=\"h2\">",
"     Cervical cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;A close association exists between infection with oncogenic strains of HPV and malignancies of the anogenital tract, including the cervix, anus, vulva, penis, and perianal skin. This association has been most thoroughly studied for diseases of the uterine cervix. The vast majority of cervical cancers are thought to be caused by HPV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A higher than expected rate of invasive and preinvasive cervical neoplasia has been reported in HIV-infected women [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. In an early series of HIV-infected women with invasive cervical cancer, therapy failed to control or eradicate the tumor, and all died with a mean survival of 10 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/9\">",
"     9",
"    </a>",
"    ]. Based upon these findings, the CDC in 1993 added moderate and severe cervical dysplasia as an early symptomatic HIV condition (category B) and invasive cervical cancer as an indicator condition in the case definition of AIDS (category C). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=see_link\">",
"     \"Preinvasive and invasive cervical neoplasia in HIV-infected women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of both cervical dysplasia and neoplasia is significantly increased in HIV-infected women, and the prevalence of cervical intraepithelial neoplasia (also called cervical squamous intraepithelial lesions) ranges between 30 and 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506284\">",
"    <span class=\"h1\">",
"     NON-AIDS-DEFINING MALIGNANCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other malignancies have either a significantly increased incidence in HIV-infected individuals compared with the non-HIV-infected population, or have an altered biology with clinically significant implications. These are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506291\">",
"    <span class=\"h2\">",
"     Hodgkin lymphoma",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506298\">",
"    <span class=\"h3\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hodgkin lymphoma (HL) is among the most common non-AIDS-defining malignancies, with an incidence 15 to 30 fold higher than in the non-HIV-infected population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2\">",
"     2",
"    </a>",
"    ]. HL appears to be significantly more common in men who have sex with men compared to those who were intravenous drug users [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Features of HL in patients with HIV infection include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unfavorable histology is substantially more common in patients with HIV infection. Mixed cellularity HL accounted for approximately 60 percent of cases in two large series [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=see_link\">",
"       \"Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Most patients with HIV-associated HL are EBV positive, with a 75 to 100 percent rate of EBV coinfection. HL tends to develop early in HIV infection. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=see_link\">",
"       \"The role of Epstein-Barr virus in Hodgkin lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The relationship between HL and CD4 cell count is unclear, with some studies indicating that HL is associated with advanced HIV-related immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/15\">",
"       15",
"      </a>",
"      ]. In the Swiss cohort study, the increased incidence with a lower CD4 count was not statistically significant [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There is conflicting evidence about the impact of potent ART on the incidence of HL. Some studies suggest that the incidence has increased in the ART era [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/16-18\">",
"       16-18",
"      </a>",
"      ], but at least one study did not observe a significant change [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/12\">",
"       12",
"      </a>",
"      ]. The risk of developing HL may be particularly increased in the first months after the initiation of ART [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506305\">",
"    <span class=\"h3\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically, HL often presents with more aggressive disease in HIV-positive patients than in non-HIV-infected persons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Systemic B symptoms (ie, fever, weight loss, night sweats) are frequent, and widely disseminated extranodal disease may be present in most patients at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Up to 40 to 50 percent may have bone marrow involvement at diagnosis. Mediastinal involvement is infrequent in HIV-infected patients. HL of the liver, spleen, and brain have been noted, as well as case reports of HIV-related HL presenting in uncommon gastrointestinal locations such as the anus and stomach [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506312\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment for HIV-related HL has not been established in randomized trials. Prior to the introduction of potent ART, treatment of HL was associated with significant toxicity and outcomes were poor [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Despite the difficulties of intensive treatment in these HIV-infected patients, contemporary regimens have given promising results in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/13,14,26,27\">",
"     13,14,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prospective and retrospective results in HIV positive patients with HL support the role of standard chemotherapy approaches in combination with ART:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most extensive results come from a German multicenter study, in which 108 HIV positive patients with HL were treated using a stage and risk-adapted approach [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/13\">",
"       13",
"      </a>",
"      ]. The 23 patients with early stage, favorable HL were treated with two to four cycles of ABVD chemotherapy followed by involved field radiation therapy (RT). The 14 patients with early stage, unfavorable HL were managed with either the more intensive BEACOPP regimen or with four cycles of ABVD plus RT. The 71 patients with advanced stage HL were managed with six to eight cycles of BEACOPP. Overall 102 of the 108 patients (94 percent) were maintained on ART during treatment for HL. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"       \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Using this stratified treatment approach, complete remission rates for early stage favorable HL, early stage unfavorable HL, and advanced stage HL were 96, 100, and 86 percent, respectively. For the entire group, the two-year progression-free survival rate was 92 percent, and the two-year overall survival rate was 91 percent after a median follow-up of 26 months.",
"     </li>",
"     <li>",
"      Similar conclusions were drawn from a retrospective study of 224 HL patients who were consecutively treated with ABVD between 1997 and 2010, in a series that included 93 patients who were HIV positive [",
"      <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/14\">",
"       14",
"      </a>",
"      ]. ART was given concurrently to 92 of the 93 (99 percent) of the HIV positive patients during chemotherapy. The patients who were HIV positive had more extensive disease and more adverse prognostic features that those who were HIV negative. However, overall survival and progression-free survival following treatment with ABVD were not adversely affected by positive HIV status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Guidelines from the British HIV association recommend that all HL patients should be treated with potent ART and that a standard chemotherapy regimen such as ABVD be used as the initial treatment of advanced disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=see_link\">",
"     \"Overview of the treatment of classical Hodgkin lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42294?source=see_link\">",
"     \"Systemic therapy for malignancy in patients on anti retroviral medications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506319\">",
"    <span class=\"h2\">",
"     Other hematologic malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected persons are at increased risk for developing other hematologic malignancies, including plasma cell disorders and leukemia, in addition to HL and non-Hodgkin lymphoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506326\">",
"    <span class=\"h3\">",
"     Plasma cell disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected patients can present with a range of plasma cell disorders, including reactive plasmacytosis, paraproteinemia, amyloidosis, light chain deposition disease, plasmacytomas, multiple myeloma, and plasma cell leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Plasma cell disorders in HIV-infected patients tend to occur at a younger age than in the general population, with an average age of 33 years in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of serum protein abnormalities with HIV infection was illustrated by a study of 320 consecutive patients, 16 percent of whom had a detectable abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/32\">",
"     32",
"    </a>",
"    ]. Overall, 8 percent had subtle oligoclonal banding and 4 percent had a low-concentration monoclonal band (&lt;5 percent of total protein). Hypogammaglobulinemia and polyclonal hypergammaglobulinemia each accounted for 2 percent. HIV-related bands may be transient or persistent. Abnormal protein bands may decrease while a patient is receiving potent ART in at least 50 percent of cases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link\">",
"     \"Recognition of monoclonal proteins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The demographic characteristics of patients with monoclonal gammopathies were illustrated by a series of 25 HIV-infected patients, in which the median age was 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/32\">",
"     32",
"    </a>",
"    ]. Multivariate analysis found that abnormalities in serum proteins were associated with a younger age, a higher HIV viral load, a more robust immune system (ie, higher CD4 cell count), and hepatitis B",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    C virus coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/28,32\">",
"     28,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subset of these patients go on to develop myeloma, plasmacytoma, or lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Extramedullary disease is common in those patients who develop multiple myeloma; such plasmacytomas can be multiple and present in unusual anatomical locations. Plasma cell malignancies may show a plasmablastic morphology, making them difficult to differentiate from plasmablastic lymphoma. Myeloma patients with concomitant HIV infection may have an increased risk of complications, including intractable hypercalcemia, hyperviscosity, cytopenia, and renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected persons diagnosed with a plasma cell disorder should be treated similar to HIV-negative patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506333\">",
"    <span class=\"h3\">",
"     Acute myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports suggested that the incidence of acute myeloid leukemia (AML) is increased in HIV-infected persons [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. However, data from the Swiss HIV Cohort study indicate that the overall incidence is similar or only modestly increased [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation and biologic features of HIV-related AML are similar to that in HIV-negative persons, although the occurrence of extramedullary leukemic infiltration (myeloid sarcoma) in this setting is not uncommon. In general, HIV-infected patients with AML can achieve complete stable remission with standard therapy. A poor prognosis has been reported, especially with CD4 cell counts &lt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With increasing use of chemotherapy for both AIDS-defining cancers and non-AIDS defining malignancies, treatment-related leukemias may become an increasing issue [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506340\">",
"    <span class=\"h2\">",
"     Hepatocellular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with HIV and either the hepatitis B virus (HBV) or the hepatitis C virus (HCV) may be associated with accelerated progression of fibrosis and an increased risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma (HCC). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=see_link&amp;anchor=H5#H5\">",
"     \"Epidemiology and etiologic associations of hepatocellular carcinoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In an analysis of over 615,000 individuals infected with HIV, the risk of HCC in individuals who were infected with HIV increased progressively over time, beginning prior to the introduction of ART and continuing up to the present (standardized incidence ratio 3.8 compared with the general population) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/40\">",
"     40",
"    </a>",
"    ]. An increasing incidence of HCC was seen in the HIV-infected and general population; this was attributed to the incidence and prevalence of HCV and to the longer survival in HIV-infected patients who were treated with ART.",
"   </p>",
"   <p>",
"    Prevention",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of infection with hepatitis viruses should be routine whenever feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=see_link\">",
"       \"Prevention of hepatitis B virus infection in the HIV-infected adult\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=see_link\">",
"       \"Treatment of hepatitis B in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=see_link\">",
"       \"Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=see_link\">",
"       \"Treatment of hepatitis C virus infection in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506361\">",
"    <span class=\"h2\">",
"     Lung cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of lung cancer is increased approximately two to four-fold for individuals infected with HIV when compared to age- and gender-matched populations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2,16,38,41,42\">",
"     2,16,38,41,42",
"    </a>",
"    ]. This relative increase has remained relatively constant before and after the introduction of ART. There is an increased prevalence of cigarette smoking in the HIV population [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], but the risk of lung cancer remains elevated even after correcting for smoking status [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of lung cancer are illustrated by a retrospective series of 75 HIV-positive patients with lung cancer, who were compared with patients in the Surveillance, Epidemiology and End Results (SEER) database [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/47\">",
"     47",
"    </a>",
"    ]. HIV-infected lung cancer patients were significantly younger (median age 50 versus 68 years). Stage and histologic types were similar to the broader lung cancer population.",
"   </p>",
"   <p>",
"    Aggressive treatment for patients with lung cancer and HIV infection is indicated if the patient's overall medical condition permits. A retrospective analysis compared 322 non-small cell lung cancer (NSCLC) patients with almost 72,000 NSCLC patients without HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/48\">",
"     48",
"    </a>",
"    ]. There were no statistically differences in overall survival when patients with stage I, II, III, or IV disease were compared on a stage by stage basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=see_link\">",
"     \"Overview of the initial evaluation, treatment and prognosis of lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506368\">",
"    <span class=\"h2\">",
"     Anogenital cancer and premalignant lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) infection has been causally linked with premalignant lesions and invasive cancers involving the anus, vulva, vagina, and penis, as well as the cervix. (See",
"    <a class=\"local\" href=\"#H1560506277\">",
"     'Cervical cancer'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Malignancies and premalignant lesions in all of these sites are significantly more common in individuals infected with HIV compared with the general population (",
"    <a class=\"graphic graphic_table graphicRef74024 \" href=\"UTD.htm?27/4/27725\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Management of these lesions follows the same general approach as in non-HIV infected people:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anal intraepithelial neoplasia and anal cancer (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"       \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=see_link\">",
"       \"Clinical features, staging, and treatment of anal cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vulvar and vaginal intraepithelial neoplasia (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6455?source=see_link\">",
"       \"Vulvar and vaginal intraepithelial neoplasia in HIV-infected women\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Carcinoma of the penis (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=see_link\">",
"       \"Carcinoma of the penis: Clinical presentation and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=see_link\">",
"       \"Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased incidence of these lesions may have important implications for screening and the use of HPV vaccine in selected cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506375\">",
"    <span class=\"h2\">",
"     Head and neck cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an approximately two- to threefold increase in the incidence of squamous cell carcinoma of the head and neck for individuals infected with HIV, with some variation depending upon the specific site of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2,16,41,42\">",
"     2,16,41,42",
"    </a>",
"    ]. Other histologic types of cancer may also be increased in the head and neck region, including lymphoepithelial carcinoma of the salivary gland, nasopharyngeal carcinoma, and Merkel cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common sites of involvement include the oral cavity, tonsillar area, and larynx. The majority of HIV-infected men with squamous cell carcinoma (SCC) of the head and neck are men who have sex with men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/50\">",
"     50",
"    </a>",
"    ], and the age at presentation appears to be younger than those not infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Up to 40 percent of the head and neck cancers in patients infected with HIV are related to human papillomavirus (HPV). Patients with HPV related cancers have a better prognosis than those with tumors that are tobacco-related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and risk factors for head and neck cancer\", section on 'Human papillomavirus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of head and neck cancer follows the same principles as that in non-HIV-infect patients, although complications are more common in HIV-infected patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=see_link\">",
"     \"Overview of head and neck cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=see_link\">",
"     \"Management and prevention of complications of head and neck cancer during initial treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=see_link\">",
"     \"Management of late complications of head and neck cancer and its treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506382\">",
"    <span class=\"h2\">",
"     Skin cancers",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506389\">",
"    <span class=\"h3\">",
"     Basal cell and squamous cell",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-infected individuals have a two to three-fold increased risk of nonmelanoma skin cancer (basal cell carcinoma [BCC] and squamous cell carcinoma [SCC]) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/2,42,52\">",
"     2,42,52",
"    </a>",
"    ]. Factors associated with the development of cutaneous malignancies included increasing age and white ethnicity. BCC is substantially more common than SCC in HIV-infected individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/17,53\">",
"     17,53",
"    </a>",
"    ]. This is in contrast to organ transplant recipients, where SCC is more frequent.",
"   </p>",
"   <p>",
"    Risk factors for BCC and SCC are similar to those in non-HIV-infected individuals. However, HIV-positive patients with BCC and SCC tend to be younger, have multiple tumors that often arise in areas not exposed to the sun, have an increased rate of recurrence, more commonly experience treatment-associated complications, and seem to have an overall poorer outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/53\">",
"     53",
"    </a>",
"    ]. Unusually aggressive skin carcinomas are a recognized complication of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\", section on 'Risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    BCCs and SCCs in HIV-infected persons should be treated as they would in their HIV-negative counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=see_link\">",
"     \"Treatment and prognosis of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=see_link\">",
"     \"Treatment of basal cell carcinomas at high risk for recurrence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=see_link\">",
"     \"Treatment and prognosis of cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=see_link\">",
"     \"Systemic treatment of advanced cutaneous squamous and basal cell carcinomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506396\">",
"    <span class=\"h3\">",
"     Melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of melanoma in patients infected with HIV may be moderately increased compared with the general population (",
"    <a class=\"graphic graphic_table graphicRef74024 \" href=\"UTD.htm?27/4/27725\">",
"     table 1",
"    </a>",
"    ). Melanomas in HIV-infected patients are often multiple, frequently metastasize, and are associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, a more extensive search for metastatic disease may be warranted at diagnosis. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=see_link\">",
"     \"Overview of the management of advanced melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506403\">",
"    <span class=\"h2\">",
"     Conjunctival cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of conjunctival squamous cell carcinoma (SCC) is significantly elevated in immunosuppressed individuals, including both those with HIV and solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/56\">",
"     56",
"    </a>",
"    ]. In HIV-infected patients, the spectrum of conjunctival involvement includes intraepithelial dysplasia, carcinoma in situ, and invasive SCC, most commonly originating in the limbus (transition zone) of the eye.",
"   </p>",
"   <p>",
"    In sub-Saharan Africa, the HIV epidemic has been associated with a dramatic increase in the incidence of conjunctival neoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The association of conjunctival SCC with HIV infection in other geographic regions is less well established, although one epidemiologic study has reported an increased incidence in North America as well [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for SCC of the conjunctiva include age greater than 50 years, high solar ultraviolet radiation exposure, geography (sub-Saharan Africa), and HPV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The relatively lower incidence in America and Europe has been attributed, at least in part, to the lower solar ultraviolet exposure associated with higher latitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conjunctival SCC in HIV-positive patients occurs much earlier in life than in their HIV-negative counterparts and may be particularly aggressive [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. Presentation ranges from eye irritation or erythema to a plaque or nodular lesion. SCC of the conjunctiva has a high propensity for local invasion into the orbit, and occasionally distant metastases occur.",
"   </p>",
"   <p>",
"    Aggressive histologic variants may be diagnosed, such as spindle cell carcinoma. A biopsy is required to distinguish leukoplakic lesions ranging from pinguecula, to intraepithelial carcinoma (dysplasia, carcinoma in situ), and invasive SCC. Patients with conjunctival cancer will need to be evaluated for eyelid infiltration, intraocular and orbital invasion, as well as metastatic disease. Treatment is mainly surgical [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential therapies include photodynamic therapy or topical treatment with either mitomycin-C [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/68,69\">",
"     68,69",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/70\">",
"     70",
"    </a>",
"    ]. In one case, an African woman with advanced HIV and conjunctival SCC invading her orbit had complete tumor regression from antiretroviral therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506410\">",
"    <span class=\"h2\">",
"     Merkel cell carcinoma and other neuroendocrine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Merkel cell carcinoma is a neuroendocrine carcinoma arising in the skin, which is etiologically linked with infection with the Merkel cell polyoma virus. The incidence of Merkel cell carcinoma is increased more than ten-fold in persons with HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=see_link\">",
"     \"Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3577?source=see_link\">",
"     \"Staging and treatment of Merkel cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other extrapulmonary neuroendocrine tumors have also been observed in people with HIV infection. These include cases of carcinoids in both typical locations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/76\">",
"     76",
"    </a>",
"    ] and unusual sites [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/77\">",
"     77",
"    </a>",
"    ], as well as more highly aggressive neuroendocrine carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506417\">",
"    <span class=\"h2\">",
"     Breast cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with HIV has at most a minor effect on the incidence of breast cancer (",
"    <a class=\"graphic graphic_table graphicRef74024 \" href=\"UTD.htm?27/4/27725\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/18,41,42\">",
"     18,41,42",
"    </a>",
"    ]. However, when breast cancer occurs in HIV-infected women, there appears to be a propensity for bilateral disease, poorly differentiated carcinomas, and early metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/79\">",
"     79",
"    </a>",
"    ]. The relatively high frequency of these poor prognosis features makes the regular screening of particular importance in HIV-infected women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link\">",
"     \"Screening for breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-positive patients with breast cancer should be treated in the same way as their HIV-negative counterparts with similarly staged disease, particularly when they have CD4 counts &gt;200",
"    <span class=\"nowrap\">",
"     cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and controlled HIV viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/79\">",
"     79",
"    </a>",
"    ]. Despite the tendency to present with more advanced disease, aggressive treatment of early breast cancer can result in a favorable outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/80\">",
"     80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=see_link\">",
"     \"Overview of the treatment of newly diagnosed, non-metastatic breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506424\">",
"    <span class=\"h2\">",
"     Gastrointestinal malignancies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506431\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a 2007 review of the literature composed primarily of patients from the pre-potent ART era did not demonstrate an increase in the incidence of colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/42\">",
"     42",
"    </a>",
"    ], a more recent study from the United States observed a 2.4 fold increase compared with the non-HIV-infected population for the period 2000 to 2003 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An increased incidence of colorectal cancer is also supported by the frequency with which precursor lesions are identified. This was illustrated by a flexible sigmoidoscopy screening study in 2382 patients, including 165 who were HIV positive, in which there was an increased prevalence of adenomas in the HIV population (26 versus 13 percent in HIV negative subjects) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/81\">",
"     81",
"    </a>",
"    ]. Advanced neoplasia (adenomas &ge;10 mm, villous histology, high-grade dysplasia, and adenocarcinoma) was also significantly more frequent (7 versus 4 percent).",
"   </p>",
"   <p>",
"    Colorectal cancer may occur at a younger age and be more aggressive in patients infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. As an example, in a series of 17 cases, the average age at diagnosis was 43 years and the majority had right-sided lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/83\">",
"     83",
"    </a>",
"    ]. Eight (47 percent) presented with stage IV disease and eight died within 26 months of diagnosis.",
"   </p>",
"   <p>",
"    The increased incidence of right-sided lesions in HIV-infected people suggests that colonoscopy may be preferable for screening, rather than flexible sigmoidoscopy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506438\">",
"    <span class=\"h3\">",
"     Stomach and esophageal malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is an increased incidence of both stomach and esophageal malignancies among people infected with HIV.",
"   </p>",
"   <p>",
"    In a database analysis of almost 600,000 HIV infected individuals, the incidence of both carcinoma of the stomach and carcinoma of the esophagus was significantly increased compared with the general population (SIRs 1.44 and 1.69, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/84\">",
"     84",
"    </a>",
"    ]. Among those with esophageal cancer, the increase was observed with both adenocarcinoma and squamous cell cancer. The incidence rates relative to the general population remained roughly constant in the pre and post-ART periods.",
"   </p>",
"   <p>",
"    In addition to carcinomas, NHLs were frequently observed. Among patients with stomach malignancies, NHLs were almost four times more frequent than carcinomas, and approximately two-thirds of these were diffuse large B-cell lymphomas. Among patients with esophageal malignancies, NHLs constituted about one-third of all cases, and the majority were diffuse large B-cell lymphomas. The relative increase in the incidence of NHL in both the esophagus and the stomach decreased with the introduction of ART. (See",
"    <a class=\"local\" href=\"#H1560506263\">",
"     'Non-Hodgkin lymphoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The management of gastric and esophageal cancers is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=see_link\">",
"     \"Early gastric cancer: Treatment, natural history, and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506445\">",
"    <span class=\"h2\">",
"     Genitourinary malignancies",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506452\">",
"    <span class=\"h3\">",
"     Prostate cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection does not have a significant effect on the incidence of prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/41,42,85\">",
"     41,42,85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=see_link\">",
"     \"Risk factors for prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although rare cases of unusually aggressive HIV-related prostate cancer have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/86,87\">",
"     86,87",
"    </a>",
"    ], the HIV status does not appear to influence PSA levels, clinical presentation, tumor grade or stage, or outcome in men with prostate cancer receiving potent ART [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/85,88,89\">",
"     85,88,89",
"    </a>",
"    ]. Furthermore, the use of radiation therapy does not appear to affect the immune system in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, patients with prostate cancer and well-controlled HIV viremia should be managed similarly to their HIV-negative counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/91\">",
"     91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"     \"Initial approach to low-risk clinically localized prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"     \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link\">",
"     \"Overview of the treatment of disseminated prostate cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506459\">",
"    <span class=\"h3\">",
"     Testicular neoplasms",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be a modest increase in the incidence of testicular malignancies in men infected with HIV compared to non-HIV-infected men [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/42\">",
"     42",
"    </a>",
"    ]. This increased risk is limited to seminomas and does not appear to affect the incidence of nonseminomatous germ cell tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Stage at presentation does not appear to be affected by HIV status, and the natural history of testicular neoplasia is similar to that encountered in HIV negative patients. There is no evidence that outcome is worse than in men who have seminoma without HIV infection, and management is the same as in men not infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/1\">",
"     1",
"    </a>",
"    ]. Long-term survival in men appears to depend upon the status of their HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/95-97\">",
"     95-97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506466\">",
"    <span class=\"h3\">",
"     Bladder cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to suggest that the incidence of bladder cancer is significantly increased in people infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/42\">",
"     42",
"    </a>",
"    ]. Nevertheless, symptoms of hematuria, dysuria, frequency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    urgency in an HIV-infected patient warrant complete evaluation, including a work up for bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=see_link\">",
"     \"Overview of the management of urothelial (transitional cell) bladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506473\">",
"    <span class=\"h3\">",
"     Renal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a review of the literature that included seven studies and 444,172 HIV-infected individuals, the relative risk of renal cell carcinoma ranged from 0.8 to 2.0 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-infected patients with RCC appear to present at a slightly younger age than those without HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/98\">",
"     98",
"    </a>",
"    ]. Those diagnosed with early stage RCC did well after surgical resection, while those who were symptomatic with advanced renal cancer at diagnosis did poorly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=see_link\">",
"     \"Prognostic factors in patients with renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506480\">",
"    <span class=\"h2\">",
"     Sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sarcomas are uncommon in HIV-infected patients. However, in a review of the literature, there was a disproportionate increase in leiomyosarcoma among those with HIV infection. Leimyosarcoma accounted for 58 percent of all sarcomas other than KS, compared with 17 percent of cases in the SEER database [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/99\">",
"     99",
"    </a>",
"    ]. There may be multiple smooth muscle tumors, often found in uncommon locations such as the CNS, lung, pericardium, pleura, spleen, adrenal gland, lymph node, and orbit [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/100,101\">",
"     100,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential role for EBV has been shown in the tumorigenesis of HIV-associated leiomyosarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/100\">",
"     100",
"    </a>",
"    ]. AIDS-associated leiomyosarcomas behave in an aggressive fashion. These tumors tend to recur despite therapy, resulting in poor survival. First-line therapy may include radiation therapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    complete local excision. The treatment of localized and metastatic sarcomas is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=see_link\">",
"     \"Surgical treatment and other localized therapy for metastatic soft tissue sarcoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506487\">",
"    <span class=\"h2\">",
"     Gestational trophoblastic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HIV is not an apparent risk factor for gestational trophoblastic neoplasia, these patients tend to present with more advanced disease, and may have a significantly worse prognosis than in women without HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/31/30202/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=see_link\">",
"     \"Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=see_link\">",
"     \"Gestational trophoblastic neoplasia: Staging and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1560506494\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early in the AIDS epidemic, a dramatic increase in Kaposi sarcoma (KS), non-Hodgkin lymphoma (NHL), and cervical cancer was noted, and these tumors ultimately were classified as AIDS-defining cancers. With the widespread use of potent antiretroviral therapy (ART), there was a dramatic decrease in the incidence of KS and NHL and a significant increase in the incidence of several other malignancies (non-AIDS-defining cancers). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link&amp;anchor=H1560489307#H1560489307\">",
"       \"HIV infection and malignancy: Epidemiology and pathogenesis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An understanding of the epidemiology and risk factors for these malignancies, in association with the prolonged survival of HIV-infected people in the ART era, increases the importance of adherence to cancer screening recommendations and prevention measures. (See",
"      <a class=\"local\" href=\"#H1560506118\">",
"       'Screening and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the biology of malignancy in HIV infected people is often more aggressive than in those without HIV infection, standard treatment is generally indicated and can be associated with a favorable outcome, depending upon the tumor type, stage, and comorbidity. (See",
"      <a class=\"local\" href=\"#H1560506125\">",
"       'Principles of treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1560506132\">",
"       'AIDS-defining malignancies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1560506284\">",
"       'Non-AIDS-defining malignancies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H196248990\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to recognize Dr. Scot Remick, who contributed to previous versions of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/1\">",
"      Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 2008; 9:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/2\">",
"      Deeken JF, Tjen-A-Looi A, Rudek MA, et al. The rising challenge of non-AIDS-defining cancers in HIV-infected patients. Clin Infect Dis 2012; 55:1228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/3\">",
"      Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/4\">",
"      Tyerman Z, Aboulafia DM. Review of screening guidelines for non-AIDS-defining malignancies: evolving issues in the era of highly active antiretroviral therapy. AIDS Rev 2012; 14:3.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.europeanaidsclinicalsociety.org/ (Accessed on August 30, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/6\">",
"      Nelson L, Fried M, Stewart K. The risks of surgery in HIV-infected patients. J Perioper Pract 2007; 17:470, 472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/7\">",
"      Harris HW, Schecter WP. Surgical risk assessment and management in patients with HIV disease. Gastroenterol Clin North Am 1997; 26:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/8\">",
"      Martin JN, Ganem DE, Osmond DH, et al. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998; 338:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/9\">",
"      Maiman M, Fruchter RG, Serur E, et al. Human immunodeficiency virus infection and cervical neoplasia. Gynecol Oncol 1990; 38:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/10\">",
"      Robinson W 3rd. Invasive and preinvasive cervical neoplasia in human immunodeficiency virus-infected women. Semin Oncol 2000; 27:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/11\">",
"      Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/12\">",
"      Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113:5737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/13\">",
"      Hentrich M, Berger M, Wyen C, et al. Stage-adapted treatment of HIV-associated Hodgkin lymphoma: results of a prospective multicenter study. J Clin Oncol 2012; 30:4117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/14\">",
"      Montoto S, Shaw K, Okosun J, et al. HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. J Clin Oncol 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/15\">",
"      Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001; 285:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/16\">",
"      Powles T, Robinson D, Stebbing J, et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 2009; 27:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/17\">",
"      Clifford GM, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/18\">",
"      Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003; 21:3447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/19\">",
"      Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood 2011; 118:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/20\">",
"      Levine AM. HIV-associated Hodgkin's disease. Biologic and clinical aspects. Hematol Oncol Clin North Am 1996; 10:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/21\">",
"      Costello R, Heuberger L, Petit N, et al. [Hodgkin's disease in patients infected with the human immunodeficiency virus]. Rev Med Interne 1998; 19:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/22\">",
"      Hilman S, Brammer C. Human immunodeficiency virus-associated Hodgkin's disease of the anal canal. Clin Oncol (R Coll Radiol) 2005; 17:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/23\">",
"      Doweiko J, Dezube BJ, Pantanowitz L. Unusual sites of Hodgkin's lymphoma: CASE 1. HIV-associated Hodgkin's lymphoma of the stomach. J Clin Oncol 2004; 22:4227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/24\">",
"      Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 2005; 10:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/25\">",
"      Kaplan LD. Management of HIV-associated Hodgkin lymphoma: how far we have come. J Clin Oncol 2012; 30:4056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/26\">",
"      Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma. Haematologica 2007; 92:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/27\">",
"      Spina M, Gabarre J, Rossi G, et al. Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection. Blood 2002; 100:1984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/28\">",
"      Dezube BJ, Aboulafia DM, Pantanowitz L. Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read 2004; 14:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/29\">",
"      Salarieh A, Rao C, Gottesman SR, et al. Plasma cell tumors in HIV-positive patients: report of a case and review of the literature. Leuk Lymphoma 2005; 46:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/30\">",
"      Amara S, Dezube BJ, Cooley TP, et al. HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clin Infect Dis 2006; 43:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/31\">",
"      Fiorino AS, Atac B. Paraproteinemia, plasmacytoma, myeloma and HIV infection. Leukemia 1997; 11:2150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/32\">",
"      Konstantinopoulos PA, Dezube BJ, Pantanowitz L, et al. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol 2007; 128:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/33\">",
"      Larussa D, Grisetti S, Pilozzi E, et al. Acute megakaryoblastic leukemia in a patient receiving HAART. Am J Hematol 2005; 80:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/34\">",
"      Manfredi R, Sabbatani S, Chiodo F. Advanced acute myelogenous leukaemia (AML) during HAART-treated HIV disease, manifesting initially as a thyroid mass. Scand J Infect Dis 2005; 37:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/35\">",
"      Breccia M, Gentile G, Martino P, et al. Acute myeloid leukemia secondary to a myelodysplastic syndrome with t(3;3) (q21;q26) in an HIV patient treated with chemotherapy and highly active antiretroviral therapy. Acta Haematol 2004; 111:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/36\">",
"      Kudva GC, Maliekel K, Richart JM, et al. Acute promyelocytic leukemia and HIV-1 infection: case report and review of the literature. Am J Hematol 2004; 77:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/37\">",
"      Aboulafia DM, Meneses M, Ginsberg S, et al. Acute myeloid leukemia in patients infected with HIV-1. AIDS 2002; 16:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/38\">",
"      Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010; 103:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/39\">",
"      Mani D, Dorer RK, Aboulafia DM. Therapy-related acute myeloid leukemia following HIV-associated lymphoma. Clin Lymphoma Myeloma 2009; 9:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/40\">",
"      Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2012; 118:6226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/41\">",
"      Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/42\">",
"      Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 2007; 370:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/43\">",
"      Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDS 2007; 21:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/44\">",
"      Clifford GM, Lise M, Franceschi S, et al. Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection. Br J Cancer 2012; 106:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/45\">",
"      Kirk GD, Merlo C, O' Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007; 45:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/46\">",
"      Chaturvedi AK, Pfeiffer RM, Chang L, et al. Elevated risk of lung cancer among people with AIDS. AIDS 2007; 21:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/47\">",
"      D'Jaen GA, Pantanowitz L, Bower M, et al. Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer 2010; 11:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/48\">",
"      Rengan R, Mitra N, Liao K, et al. Effect of HIV on survival in patients with non-small-cell lung cancer in the era of highly active antiretroviral therapy: a population-based study. Lancet Oncol 2012; 13:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/49\">",
"      Purgina B, Pantanowitz L, Seethala RR. A Review of Carcinomas Arising in the Head and Neck Region in HIV-Positive Patients. Patholog Res Int 2011; 2011:469150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/50\">",
"      Roland JT Jr, Rothstein SG, Mittal KR, Perksy MS. Squamous cell carcinoma in HIV-positive patients under age 45. Laryngoscope 1993; 103:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/51\">",
"      Singh B, Sabin S, Rofim O, et al. Alterations in head and neck cancer occurring in HIV-infected patients--results of a pilot, longitudinal, prospective study. Acta Oncol 1999; 38:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/52\">",
"      Silverberg MJ, Leyden W, Warton EM, et al. HIV Infection Status, Immunodeficiency, and the Incidence of Non-Melanoma Skin Cancer. J Natl Cancer Inst 2013; 105:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/53\">",
"      Wilkins K, Turner R, Dolev JC, et al. Cutaneous malignancy and human immunodeficiency virus disease. J Am Acad Dermatol 2006; 54:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/54\">",
"      Neves-Motta R, Ferry FR, Bas&iacute;lio-de-Oliveira CA, et al. Highly aggressive squamous cell carcinoma in an HIV-infected patient. Rev Soc Bras Med Trop 2004; 37:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/55\">",
"      Hoffmann C, Horst HA, Weichenthal M, Hauschild A. Malignant melanoma and HIV infection -- aggressive course despite immune reconstitution. Onkologie 2005; 28:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/56\">",
"      Shields CL, Ramasubramanian A, Mellen PL, Shields JA. Conjunctival squamous cell carcinoma arising in immunosuppressed patients (organ transplant, human immunodeficiency virus infection). Ophthalmology 2011; 118:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/57\">",
"      Chisi SK, Kollmann MK, Karimurio J. Conjunctival squamous cell carcinoma in patients with human immunodeficiency virus infection seen at two hospitals in Kenya. East Afr Med J 2006; 83:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/58\">",
"      Makupa II, Swai B, Makupa WU, et al. Clinical factors associated with malignancy and HIV status in patients with ocular surface squamous neoplasia at Kilimanjaro Christian Medical Centre, Tanzania. Br J Ophthalmol 2012; 96:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/59\">",
"      Guech-Ongey M, Engels EA, Goedert JJ, et al. Elevated risk for squamous cell carcinoma of the conjunctiva among adults with AIDS in the United States. Int J Cancer 2008; 122:2590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/60\">",
"      Ateenyi-Agaba C, Franceschi S, Wabwire-Mangen F, et al. Human papillomavirus infection and squamous cell carcinoma of the conjunctiva. Br J Cancer 2010; 102:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/61\">",
"      Moubayed P, Mwakyoma H, Schneider DT. High frequency of human papillomavirus 6/11, 16, and 18 infections in precancerous lesions and squamous cell carcinoma of the conjunctiva in subtropical Tanzania. Am J Clin Pathol 2004; 122:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/62\">",
"      Newton R, Ferlay J, Reeves G, et al. Effect of ambient solar ultraviolet radiation on incidence of squamous-cell carcinoma of the eye. Lancet 1996; 347:1450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/63\">",
"      Timm A, Stropahl G, Schittkowski M, et al. [Association of malignant tumors of the conjunctiva and HIV infection in Kinshasa (D. R. Congo). First results]. Ophthalmologe 2004; 101:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/64\">",
"      De Silva DJ, Tumuluri K, Joshi N. Conjunctival squamous cell carcinoma: atypical presentation of HIV. Clin Experiment Ophthalmol 2005; 33:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/65\">",
"      Cervantes G, Rodr&iacute;guez AA Jr, Leal AG. Squamous cell carcinoma of the conjunctiva: clinicopathological features in 287 cases. Can J Ophthalmol 2002; 37:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/66\">",
"      Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea 2003; 22:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/67\">",
"      Gichuhi S, Irlam JJ. Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane Database Syst Rev 2007; :CD005643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/68\">",
"      Barbazetto IA, Lee TC, Abramson DH. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am J Ophthalmol 2004; 138:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/69\">",
"      Prabhasawat P, Tarinvorakup P, Tesavibul N, et al. Topical 0.002% mitomycin C for the treatment of conjunctival-corneal intraepithelial neoplasia and squamous cell carcinoma. Cornea 2005; 24:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/70\">",
"      Sturges A, Butt AL, Lai JE, Chodosh J. Topical interferon or surgical excision for the management of primary ocular surface squamous neoplasia. Ophthalmology 2008; 115:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/71\">",
"      Holkar S, Mudhar HS, Jain A, et al. Regression of invasive conjunctival squamous carcinoma in an HIV-positive patient on antiretroviral therapy. Int J STD AIDS 2005; 16:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/72\">",
"      Engels EA, Frisch M, Goedert JJ, et al. Merkel cell carcinoma and HIV infection. Lancet 2002; 359:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/73\">",
"      Lanoy E, Dores GM, Madeleine MM, et al. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS 2009; 23:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/74\">",
"      Wieland U, Kreuter A. Merkel cell polyomavirus infection and Merkel cell carcinoma in HIV-positive individuals. Curr Opin Oncol 2011; 23:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/75\">",
"      Wieland U, Silling S, Scola N, et al. Merkel cell polyomavirus infection in HIV-positive men. Arch Dermatol 2011; 147:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/76\">",
"      Pantanowitz L, Garc&iacute;a-Caballero T, Dezube BJ. Growth hormone receptor (GH)-expressing carcinoid tumors after recombinant human GH therapy for human immunodeficiency virus-related lipodystrophy. Clin Infect Dis 2003; 36:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/77\">",
"      Coleman H, Kennedy M, Altini M, et al. Neuroendocrine (carcinoid) tumor of the mandible: a case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/78\">",
"      Lito P, Pantanowitz L, Marotti J, et al. Gastroenteropancreatic neuroendocrine tumors in patients with HIV infection: a trans-Atlantic series. Am J Med Sci 2009; 337:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/79\">",
"      Gewurz BE, Dezube BJ, Pantanowitz L. HIV and the breast. AIDS Read 2005; 15:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/80\">",
"      Oluwole SF, Ali AO, Shafaee Z, DePaz HA. Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature. J Surg Oncol 2005; 89:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/81\">",
"      Bini EJ, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006; 166:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/82\">",
"      Yeg&uuml;ez JF, Martinez SA, Sands DR, et al. Colorectal malignancies in HIV-positive patients. Am Surg 2003; 69:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/83\">",
"      Chapman C, Aboulafia DM, Dezube BJ, Pantanowitz L. Human immunodeficiency virus-associated adenocarcinoma of the colon: clinicopathologic findings and outcome. Clin Colorectal Cancer 2009; 8:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/84\">",
"      Persson EC, Shiels MS, Dawsey SM, et al. Increased risk of stomach and esophageal malignancies in people with AIDS. Gastroenterology 2012; 143:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/85\">",
"      Pantanowitz L, Bohac G, Cooley TP, et al. Human immunodeficiency virus-associated prostate cancer: clinicopathological findings and outcome in a multi-institutional study. BJU Int 2008; 101:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/86\">",
"      Furco A, Bani-Sadr F, Guymar S, Molina JM. [Metastatic cancer of the prostate in a young 40 year-old HIV-infected male patient]. Presse Med 2003; 32:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/87\">",
"      Manfredi R, Fulgaro C, Sabbatani S, et al. Disseminated, lethal prostate cancer during human immunodeficiency virus infection presenting with non-specific features. Open questions for urologists, oncologists, and infectious disease specialists. Cancer Detect Prev 2006; 30:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/88\">",
"      Levinson A, Nagler EA, Lowe FC. Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology 2005; 65:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/89\">",
"      Huang WC, Kwon EO, Scardino PT, Eastham JA. Radical prostatectomy in patients infected with human immunodeficiency virus. BJU Int 2006; 98:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/90\">",
"      Ng T, Stein NF, Kaminetsky J, et al. Preliminary results of radiation therapy for prostate cancer in human immunodeficiency virus-positive patients. Urology 2008; 72:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/91\">",
"      Wosnitzer MS, Lowe FC. Management of prostate cancer in HIV-positive patients. Nat Rev Urol 2010; 7:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/92\">",
"      Hentrich MU, Brack NG, Schmid P, et al. Testicular germ cell tumors in patients with human immunodeficiency virus infection. Cancer 1996; 77:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/93\">",
"      Lyter DW, Bryant J, Thackeray R, et al. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 1995; 13:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/94\">",
"      Powles T, Bower M, Daugaard G, et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J Clin Oncol 2003; 21:1922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/95\">",
"      Bernardi D, Salvioni R, Vaccher E, et al. Testicular germ cell tumors and human immunodeficiency virus infection: a report of 26 cases. Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13:2705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/96\">",
"      Fizazi K, Amato RJ, Beuzeboc P, et al. Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer 2001; 92:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/97\">",
"      Powles T, Bower M, Shamash J, et al. Outcome of patients with HIV-related germ cell tumours: a case-control study. Br J Cancer 2004; 90:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/98\">",
"      Gaughan EM, Dezube BJ, Aboulafia D, et al. Human immunodeficiency virus--associated renal cell carcinoma: a transatlantic case series. Clin Genitourin Cancer 2008; 6:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/99\">",
"      Bhatia K, Shiels MS, Berg A, Engels EA. Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review. Curr Opin Oncol 2012; 24:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/100\">",
"      Jenson HB. Review: Epstein-Barr virus-associated smooth muscle tumors. Clin Adv Hematol Oncol 2010; 8:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/101\">",
"      Purgina B, Rao UN, Miettinen M, Pantanowitz L. AIDS-Related EBV-Associated Smooth Muscle Tumors: A Review of 64 Published Cases. Patholog Res Int 2011; 2011:561548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/102\">",
"      Tayib S, van Wijk L, Denny L. Gestational trophoblastic neoplasia and human immunodeficiency virus infection: a 10-year review. Int J Gynecol Cancer 2011; 21:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/31/30202/abstract/103\">",
"      Moodley M, Budhram S, Connolly C. Profile of mortality among women with gestational trophoblastic disease infected with the human immunodeficiency virus (HIV): argument for a new poor prognostic factor. Int J Gynecol Cancer 2009; 19:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8036 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30202=[""].join("\n");
var outline_f29_31_30202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1560506494\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506014\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506021\">",
"      CLINICAL IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506118\">",
"      Screening and prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506125\">",
"      Principles of treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506132\">",
"      AIDS-DEFINING MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506256\">",
"      Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506263\">",
"      Non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506277\">",
"      Cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506284\">",
"      NON-AIDS-DEFINING MALIGNANCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506291\">",
"      Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506298\">",
"      - Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506305\">",
"      - Natural history",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506312\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506319\">",
"      Other hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506326\">",
"      - Plasma cell disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506333\">",
"      - Acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506340\">",
"      Hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506361\">",
"      Lung cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506368\">",
"      Anogenital cancer and premalignant lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506375\">",
"      Head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506382\">",
"      Skin cancers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506389\">",
"      - Basal cell and squamous cell",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506396\">",
"      - Melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506403\">",
"      Conjunctival cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506410\">",
"      Merkel cell carcinoma and other neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506417\">",
"      Breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506424\">",
"      Gastrointestinal malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506431\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506438\">",
"      - Stomach and esophageal malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506445\">",
"      Genitourinary malignancies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506452\">",
"      - Prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506459\">",
"      - Testicular neoplasms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506466\">",
"      - Bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506473\">",
"      - Renal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506480\">",
"      Sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506487\">",
"      Gestational trophoblastic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1560506494\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H196248990\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/8036\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/8036|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/53/852\" title=\"picture 1A\">",
"      AIDS-related Kaposis sarcoma - nose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/59/13237\" title=\"picture 1B\">",
"      AIDS-related Kaposis sarcoma - face",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/32/31238\" title=\"picture 1C\">",
"      AIDS-related Kaposis sarcoma - plaque",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/35/24113\" title=\"picture 1D\">",
"      AIDS-related Kaposis sarcoma - multiple plaques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/20/30018\" title=\"picture 1E\">",
"      Erythematous leg lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/21/23894\" title=\"picture 1F\">",
"      KS erythematous papules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/62/24548\" title=\"picture 1G\">",
"      AIDS-related Kaposis sarcoma - papules on leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/23/42354\" title=\"picture 1H\">",
"      AIDS-related Kaposis sarcoma - penis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/20/34114\" title=\"picture 1I\">",
"      AIDS-related Kaposis sarcoma - sole of foot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/61/11220\" title=\"picture 1J\">",
"      AIDS-related Kaposis sarcoma - ulcerating",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/16/18693\" title=\"picture 2A\">",
"      AIDS-related Kaposis sarcoma - gingiva",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/44/39617\" title=\"picture 2B\">",
"      AIDS-related Kaposis sarcoma - palate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/31/29169\" title=\"picture 3\">",
"      KS involvement of colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/8036|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/4/27725\" title=\"table 1\">",
"      NonAIDS cancer SIRs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12103?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/37/18009?source=related_link\">",
"      AIDS-related Kaposi sarcoma: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/21/42328?source=related_link\">",
"      Carcinoma of the penis: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26840?source=related_link\">",
"      Carcinoma of the penis: Epidemiology, risk factors, staging, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/35/6712?source=related_link\">",
"      Clinical features and diagnosis of Merkel cell (neuroendocrine) carcinoma and sebaceous cell carcinoma of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4842?source=related_link\">",
"      Early gastric cancer: Treatment, natural history, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/38/25194?source=related_link\">",
"      Epidemiology and etiologic associations of hepatocellular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20583?source=related_link\">",
"      Epidemiology and risk factors for head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7033?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/32/30218?source=related_link\">",
"      Epidemiology, natural history, and diagnosis of hepatitis C in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/13/15578?source=related_link\">",
"      Epidemiology, pathologic features, and diagnosis of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/11/24761?source=related_link\">",
"      Gestational trophoblastic disease: Epidemiology, clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/15/42234?source=related_link\">",
"      Gestational trophoblastic neoplasia: Staging and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22554?source=related_link\">",
"      Management and prevention of complications of head and neck cancer during initial treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/42/30378?source=related_link\">",
"      Management of late complications of head and neck cancer and its treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30407?source=related_link\">",
"      Overview of head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/3/23609?source=related_link\">",
"      Overview of smoking cessation management in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/61/13273?source=related_link\">",
"      Overview of the initial evaluation, treatment and prognosis of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15558?source=related_link\">",
"      Overview of the management of advanced melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/44/2759?source=related_link\">",
"      Overview of the management of urothelial (transitional cell) bladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/12/13512?source=related_link\">",
"      Overview of the treatment of classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19177?source=related_link\">",
"      Overview of the treatment of newly diagnosed, non-metastatic breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18665?source=related_link\">",
"      Preinvasive and invasive cervical neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/10/40104?source=related_link\">",
"      Prevention of hepatitis B virus infection in the HIV-infected adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/44/21192?source=related_link\">",
"      Prognostic factors in patients with renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=related_link\">",
"      Pulmonary involvement in AIDS-related Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/52/31562?source=related_link\">",
"      Risk factors for prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/31/3577?source=related_link\">",
"      Staging and treatment of Merkel cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44680?source=related_link\">",
"      Surgical treatment and other localized therapy for metastatic soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42294?source=related_link\">",
"      Systemic therapy for malignancy in patients on anti retroviral medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7354?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/61/14293?source=related_link\">",
"      Systemic treatment of advanced cutaneous squamous and basal cell carcinomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/39/3703?source=related_link\">",
"      The role of Epstein-Barr virus in Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13690?source=related_link\">",
"      Treatment and prognosis of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31209?source=related_link\">",
"      Treatment and prognosis of cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/8/24712?source=related_link\">",
"      Treatment of basal cell carcinomas at high risk for recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16185?source=related_link\">",
"      Treatment of hepatitis B in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/38/18026?source=related_link\">",
"      Treatment of hepatitis C virus infection in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6455?source=related_link\">",
"      Vulvar and vaginal intraepithelial neoplasia in HIV-infected women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_31_30203="Comparison of bronchiolitis II";
var content_f29_31_30203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F60031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F60031&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Proliferative versus constrictive bronchiolitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Proliferative bronchiolitis",
"      </td>",
"      <td class=\"subtitle1\">",
"       Constrictive bronchiolitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Selected clinical syndromes",
"      </td>",
"      <td>",
"       <p>",
"        Cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans with organizing pneumonia)",
"       </p>",
"       <p>",
"        Collagen vascular disease (eg, dermatomyositis, SLE)",
"       </p>",
"       <p>",
"        Chronic \"organizing\" pneumonia (especially influenza, Mycoplasma, Pneumocystis carinii)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        Allograft recipients (bone marrow, heart-lung, lung)",
"       </p>",
"       <p>",
"        Collagen vascular disease (rheumatoid arthritis)",
"       </p>",
"       <p>",
"        Post-infectious (especially respiratory syncytial virus, adenovirus, influenza, parainfluenza, Mycoplasma)",
"       </p>",
"       <p>",
"        Inhaled toxins (eg, nitrogen dioxide, sulfur dioxide, ammonia, chlorine, phosgene)",
"       </p>",
"       <p>",
"        Drugs (eg, penicillamine, lomustine)",
"       </p>",
"       <p>",
"        Cigarette smoke",
"       </p>",
"       <p>",
"        Mineral dust airway disease",
"       </p>",
"       <p>",
"        Idiopathic",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Natural history",
"      </td>",
"      <td>",
"       Glucocorticoid responsive and usually reversible",
"      </td>",
"      <td>",
"       Relatively glucocorticoid unresponsive and usually progressive, with the development of irreversible airflow obstruction and air trapping",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from King, TE Jr, Clin Chest Med 1993; 14:607.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30203=[""].join("\n");
var outline_f29_31_30203=null;
var title_f29_31_30204="Complications in preeclampsia";
var content_f29_31_30204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Complications of preeclampsia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Outcome measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal blood pressure, (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mild preeclampsia (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Severe preeclampsia (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Maternal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver dysfunction",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        20.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kidney dysfunction",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"       <td>",
"        5.1",
"       </td>",
"       <td>",
"        12.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Placental abruption",
"       </td>",
"       <td>",
"        0.7",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        3.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Induced labor",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        41.5",
"       </td>",
"       <td>",
"        58.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cesarean delivery",
"       </td>",
"       <td>",
"        13.3",
"       </td>",
"       <td>",
"        30.9",
"       </td>",
"       <td>",
"        34.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Delivery &lt;34 weeks",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        1.9",
"       </td>",
"       <td>",
"        18.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Fetal or neonatal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Growth restriction",
"       </td>",
"       <td>",
"        4.2",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        18.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Admission to NICU",
"       </td>",
"       <td>",
"        12.9",
"       </td>",
"       <td>",
"        27.3",
"       </td>",
"       <td>",
"        42.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Respiratory difficulty",
"       </td>",
"       <td>",
"        3.8",
"       </td>",
"       <td>",
"        3.2",
"       </td>",
"       <td>",
"        15.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brain hemorrhage",
"       </td>",
"       <td>",
"        0.2",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fetal death",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neonatal death",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        0.9",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Hauth, JC, Ewell, MG, Levine, RJ, et al. Obstet Gynecol 2000; 95:24.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30204=[""].join("\n");
var outline_f29_31_30204=null;
var title_f29_31_30205="ANA disease associations I";
var content_f29_31_30205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity and specificity of different antinuclear antibodies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"1\" rowspan=\"2\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"8\" rowspan=\"1\">",
"       Antibody",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       ds DNA",
"      </td>",
"      <td class=\"subtitle2\">",
"       ss DNA",
"      </td>",
"      <td class=\"subtitle2\">",
"       Histone",
"      </td>",
"      <td class=\"subtitle2\">",
"       Nucleoprotein",
"      </td>",
"      <td class=\"subtitle2\">",
"       Sm",
"      </td>",
"      <td class=\"subtitle2\">",
"       RNP",
"      </td>",
"      <td class=\"subtitle2\">",
"       Ro",
"      </td>",
"      <td class=\"subtitle2\">",
"       La",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       SLE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       70 percent",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       30-80",
"      </td>",
"      <td>",
"       58",
"      </td>",
"      <td>",
"       30",
"      </td>",
"      <td>",
"       27",
"      </td>",
"      <td>",
"       25-35",
"      </td>",
"      <td>",
"       15",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       95 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       96 percent",
"      </td>",
"      <td>",
"       82 percent",
"      </td>",
"      <td>",
"       87-94",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Drug LE",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       80",
"      </td>",
"      <td>",
"       95",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       1-5 percent",
"      </td>",
"      <td>",
"       50",
"      </td>",
"      <td>",
"       high",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       RA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       25",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       47",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       low",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       1 percent",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Scleroderma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       20",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       PM/DM",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       &lt;1 percent",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"9\">",
"       Sj&ouml;gren's",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sen",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       1-5 percent",
"      </td>",
"      <td>",
"       5-60",
"      </td>",
"      <td>",
"       8-70",
"      </td>",
"      <td>",
"       14-60",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spec",
"      </td>",
"      <td>",
"       1-5 percent",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       low",
"      </td>",
"      <td>",
"       mod",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       87",
"      </td>",
"      <td>",
"       94",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Sen: sensitivity; Spec: specificity.",
"     <br>",
"      Other associations: RNP: Mixed connective tissue disease (MCTD); Ro: Subacute cutaneous lupus erythematosus, Primary biliary cirrhosis, Vasculitis, Congenital heart block.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30205=[""].join("\n");
var outline_f29_31_30205=null;
var title_f29_31_30206="Differences in urinary albumin multiple myeloma and amyloidosis";
var content_f29_31_30206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F87690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F87690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 498px\">",
"   <div class=\"ttl\">",
"    Graph showing differences in urinary albumin excretion among patients with multiple myeloma and amyloidosis, acute tubular necrosis, light chain deposition disease, and cast nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 478px; height: 300px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AL = Amyloidosis",
"     <br>",
"      ATN = Acute tubular necrosis",
"      <br>",
"       LCDD = Light chain deposition disease",
"       <br>",
"        CN = Cast nephropathy",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Leung N, Gertz M, Kyle RA, et al. Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases. Clin J Am Soc Nephrol 2012; 7:1964. Copyright &copy; 2012 American Society of Nephrology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30206=[""].join("\n");
var outline_f29_31_30206=null;
var title_f29_31_30207="Jefferson C1 arch fracture lateral xray";
var content_f29_31_30207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    C1 arch fractures: Jefferson fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral radiograph shows increased predental space between C1 and the odontoid (red arrow). Also note the soft tissue swelling anterior to the site of injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_31_30207=[""].join("\n");
var outline_f29_31_30207=null;
